HEDAYA OMAR (US)
WO2016077837A1 | 2016-05-19 | |||
WO2023086295A2 | 2023-05-19 | |||
WO2023086292A2 | 2023-05-19 | |||
WO2008101157A1 | 2008-08-21 | |||
WO2009006478A2 | 2009-01-08 | |||
WO2008150729A2 | 2008-12-11 | |||
WO2008154401A2 | 2008-12-18 | |||
WO2004106356A1 | 2004-12-09 | |||
WO1994014226A1 | 1994-06-23 | |||
WO2005021570A1 | 2005-03-10 | |||
WO2007134181A2 | 2007-11-22 | |||
WO2013033230A1 | 2013-03-07 | |||
WO2012037254A1 | 2012-03-22 |
US20200048612A1 | 2020-02-13 | |||
US199662633737P | ||||
US5858988A | 1999-01-12 | |||
US6291438B1 | 2001-09-18 | |||
US5684143A | 1997-11-04 | |||
US9550988B2 | 2017-01-24 | |||
US9045754B2 | 2015-06-02 | |||
US7399845B2 | 2008-07-15 | |||
US20040171570A1 | 2004-09-02 | |||
US7427672B2 | 2008-09-23 | |||
US7053207B2 | 2006-05-30 | |||
US6268490B1 | 2001-07-31 | |||
US6770748B2 | 2004-08-03 | |||
US6794499B2 | 2004-09-21 | |||
US7034133B2 | 2006-04-25 | |||
US6525191B1 | 2003-02-25 | |||
US6670461B1 | 2003-12-30 | |||
US20070287831A1 | 2007-12-13 | |||
US20080039618A1 | 2008-02-14 | |||
US12915408A | 2008-05-29 | |||
USPP60989574P | ||||
USPP61026995P | ||||
USPP61026998P | ||||
USPP61056564P | ||||
USPP61086231P | ||||
USPP61097787P | ||||
USPP61099844P | ||||
US20080064591W | 2008-05-22 | |||
US20080066154W | 2008-06-06 | |||
US20080068922W | 2008-07-01 | |||
US20050130923A1 | 2005-06-16 | |||
US5698685A | 1997-12-16 | |||
US5166315A | 1992-11-24 | |||
US5185444A | 1993-02-09 | |||
US5034506A | 1991-07-23 | |||
US3687808A | 1972-08-29 | |||
US4845205A | 1989-07-04 | |||
US5130302A | 1992-07-14 | |||
US5134066A | 1992-07-28 | |||
US5175273A | 1992-12-29 | |||
US5367066A | 1994-11-22 | |||
US5432272A | 1995-07-11 | |||
US5457187A | 1995-10-10 | |||
US5459255A | 1995-10-17 | |||
US5484908A | 1996-01-16 | |||
US5502177A | 1996-03-26 | |||
US5525711A | 1996-06-11 | |||
US5552540A | 1996-09-03 | |||
US5587469A | 1996-12-24 | |||
US5594121A | 1997-01-14 | |||
US5596091A | 1997-01-21 | |||
US5614617A | 1997-03-25 | |||
US5645985A | 1997-07-08 | |||
US5681941A | 1997-10-28 | |||
US5750692A | 1998-05-12 | |||
US5763588A | 1998-06-09 | |||
US5830653A | 1998-11-03 | |||
US6005096A | 1999-12-21 | |||
US5994517A | 1999-11-30 | |||
US6300319B1 | 2001-10-09 | |||
US6660720B2 | 2003-12-09 | |||
US6906182B2 | 2005-06-14 | |||
US7262177B2 | 2007-08-28 | |||
US7491805B2 | 2009-02-17 | |||
US8106022B2 | 2012-01-31 | |||
US7723509B2 | 2010-05-25 | |||
US20060148740A1 | 2006-07-06 | |||
US20110123520A1 | 2011-05-26 | |||
US5897945A | 1999-04-27 | |||
US6759199B2 | 2004-07-06 | |||
US6747002B2 | 2004-06-08 |
MATHISON MEGUMI ET AL: "Cardiac reprogramming factor Gata4 reduces postinfarct cardiac fibrosis through direct repression of the profibrotic mediator snail", THE JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, vol. 154, no. 5, 21 June 2017 (2017-06-21), pages 1601 - 1610, XP085213743, ISSN: 0022-5223, DOI: 10.1016/J.JTCVS.2017.06.035
JAE-SUN PARK ET AL: "Isolation of a ventricle-specific promoter for the zebrafish ventricular myosin heavy chain (vmhc) gene and its regulation by GATA factors during embryonic heart development", DEVELOPMENTAL DYNAMICS, vol. 238, no. 6, 13 May 2009 (2009-05-13), pages 1574 - 1581, XP071970528, ISSN: 1058-8388, DOI: 10.1002/DVDY.21964
XUE-HAI LIANG ET AL: "Antisense oligonucleotides targeting translation inhibitory elements in 5' UTRs can selectively increase protein levels", NUCLEIC ACIDS RESEARCH, vol. 45, no. 16, 21 July 2017 (2017-07-21), GB, pages 9528 - 9546, XP055477254, ISSN: 0305-1048, DOI: 10.1093/nar/gkx632
LIANG XUE-HAI ET AL: "Specific Increase of Protein Levels by Enhancing Translation Using Antisense Oligonucleotides Targeting Upstream Open Frames", RNA ACTIVATION; IN: ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY, vol. 983, 2017, pages 129 - 146, XP009530685, ISBN: 978-981-10-4310-9, Retrieved from the Internet
PENG, Y. ET AL.: "Secondary Structure And Antisense Oligonucleotides Regulate Cardiac Messenger RNA Translation And Modulates Cardiomyocyte Hypertrophy", CIRCULATION RESEARCH, vol. 131, AP2055, 14 November 2022 (2022-11-14), XP093103898, Retrieved from the Internet
HEDAYA OMAR M. ET AL: "Secondary structures that regulate mRNA translation provide insights for ASO-mediated modulation of cardiac hypertrophy", NATURE COMMUNICATIONS, vol. 14, no. 1, 6166, 3 October 2023 (2023-10-03), pages 1 - 17, XP093102245, Retrieved from the Internet
HERDEWIJN, ANTISENSE NUCLEIC ACID DRUG DEV., vol. 4, 10 August 2000 (2000-08-10), pages 297 - 310
ECKSTEIN, ANTISENSE NUCLEIC ACID DRUG DEV., vol. 2, 10 April 2000 (2000-04-10), pages 117 - 21
RUSCKOWSKI ET AL., ANTISENSE NUCLEIC ACID DRUG DEV., vol. 5, 10 October 2000 (2000-10-10), pages 333 - 45
STEIN, ANTISENSE NUCLEIC ACID DRUG DEV., vol. 5, 11 October 2001 (2001-10-11), pages 317 - 25
VOROBJEV ET AL., ANTISENSE NUCLEIC ACID DRUG DEV., vol. 2, April 2001 (2001-04-01), pages 77 - 85
CHATTOPADHYAYA ET AL., J. ORG. CHEM., vol. 74, 2009, pages 118 - 134
SINGH ET AL., CHEM. COMMUN., vol. 4, 1998, pages 455 - 456
KOSHKIN ET AL., TETRAHEDRON, vol. 54, 1998, pages 3607 - 3630
WAHLESTEDT ET AL., PROC. NATL. ACAD. SCI. U.S.A, vol. 97, 2000, pages 5633 - 5638
KUMAR ET AL., BIOORG. MED. CHEM. LETT., vol. 8, 1998, pages 2219 - 2222
SINGH ET AL., J. ORG. CHEM., vol. 63, 1998, pages 10035 - 10039
SRIVASTAVA ET AL., J. AM. CHEM. SOC., vol. 129, no. 26, 4 July 2007 (2007-07-04), pages 8362 - 8379
ELAYADI ET AL., CURR. OPINION INVENS. DRUGS, vol. 2, 2001, pages 558 - 561
BRAASCH ET AL., CHEM. BIOL., vol. 8, 2001, pages 1 - 7
ORUM ET AL., CURR. OPINION MOL. THER., vol. 3, 2001, pages 239 - 243
FRIEDEN ET AL., NUCLEIC ACIDS RESEARCH, vol. 21, 2003, pages 6365 - 6372
FREIER ET AL., NUCLEIC ACIDS RESEARCH, vol. 25, no. 22, 1997, pages 4429 - 4443
ALBAEK ET AL., J. ORG. CHEM., vol. 71, 2006, pages 7731 - 7740
LEUMANN, C J., BIOORG. & MED. CHEM., vol. 10, 2002, pages 841 - 854
LEUMANN, J C, BIOORGANIC & MEDICINAL CHEMISTRY, vol. 10, 2002, pages 841 - 854
BRAASCH ET AL., BIOCHEMISTRY, vol. 41, 2002, pages 4503 - 4510
SRIVASTAVA ET AL., J. AM. CHEM. SOC., vol. 129, no. 26, 2007, pages 8362 - 8379
KABANOV ET AL., FEBS LETT., vol. 259, 1990, pages 327 - 330
SAISON-BEHMOARAS ET AL., EMBO J., vol. 10, 1991, pages 1111 - 1118
MANOHARAN ET AL., BIOORG. MED. CHEM. LET., vol. 3, 1993, pages 2765 - 2770
"ACS Symposium Series", vol. 580, article "Carbohydrate Modifications in Antisense Research", pages: 40 - 65
MAIER ET AL.: "Synthesis of Antisense Oligonucleotides Conjugated to a Multivalent Carbohydrate Cluster for Cellular Targeting", BIOCONJUGATE CHEMISTRY, vol. 14, 2003, pages 18 - 29, XP002510288, DOI: 10.1021/bc020028v
RENSEN ET AL.: "Design and Synthesis of Novel N-Acetylgalactosamine-Terminated Glycolipids for Targeting of Lipoproteins to the Hepatic Asiaglycoprotein Receptor", J. MED. CHEM., vol. 47, 2004, pages 5798 - 5808, XP002551237, DOI: 10.1021/jm049481d
BIESSEN ET AL.: "The Cholesterol Derivative of a Triantennary Galactoside with High Affinity for the Hepatic Asialoglycoprotein Receptor: a Potent Cholesterol Lowering Agent", J. MED. CHEM., vol. 38, 1995, pages 1846 - 1852, XP002552046, DOI: 10.1021/jm00011a003
BIESSEN ET AL.: "Synthesis of Cluster Galactosides with High Affinity for the Hepatic Asialoglycoprotein Receptor", J. MED. CHEM., vol. 38, 1995, pages 1538 - 1546, XP002552047, DOI: 10.1021/jm00009a014
LEE ET AL.: "New and more efficient multivalent 50daman-ligands for asialoglycoprotein receptor of mammalian hepatocytes", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 19, 2011, pages 2494 - 2500, XP055590519, DOI: 10.1016/j.bmc.2011.03.027
RENSEN ET AL.: "Determination of the Upper Size Limit for Uptake and Processing of Ligands by the Asialoglycoprotein Receptor on Hepatocytes in Vitro and in Vivo", J. BIOL. CHEM., vol. 276, no. 40, 2001, pages 37577 - 37584, XP003010766, DOI: 10.1074/jbc.M101786200
RENSEN ET AL.: "Design and Synthesis of Novel N-Acetylgalactosamine-Terminated Glycolipids for Targeting of Lipoproteins to the Hepatic Asialoglycoprotein Receptor", J. MED. CHEM., vol. 47, 2004, pages 5798 - 5808, XP002551237, DOI: 10.1021/jm049481d
SLIEDREGT ET AL.: "Design and Synthesis of Novel Amphiphilic Dendritic Galactosides for Selective Targeting of Liposomes to the Hepatic Asialoglycoprotein Receptor", J. MED. CHEM., vol. 42, 1999, pages 609 - 618, XP002552045, DOI: 10.1021/jm981078h
VALENTIJN ET AL.: "Solid-phase synthesis of lysine-based cluster galactosides with high affinity for the Asialoglycoprotein Receptor", TETRAHEDRON, vol. 53, no. 2, 1997, pages 759 - 770, XP004105178, DOI: 10.1016/S0040-4020(96)01018-6
LETSINGER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 86, 1989, pages 6553 - 6556
MANOHARAN ET AL., BIOORG. MED. CHEM. LET., vol. 4, 1994, pages 1053 - 1060
MANOHARAN ET AL., ANN. N.Y. ACAD. SCI., vol. 660, 1992, pages 306 - 309
OBERHAUSER ET AL., NUCL. ACIDS RES., vol. 20, 1992, pages 533 - 538
SVINARCHUK ET AL., BIOCHIMIE, vol. 75, 1993, pages 49 - 54
MANOHARAN ET AL., TETRAHEDRON LETT., vol. 36, 1995, pages 3651 - 3654
SHEA ET AL., NUCL. ACIDS RES., vol. 18, 1990, pages 3777 - 3783
MANOHARAN ET AL., NUCLEOSIDES & NUCLEOTIDES, vol. 14, 1995, pages 969 - 973
MISHRA ET AL., BIOCHIM. BIOPHYS. ACTA, vol. 1264, 1995, pages 229 - 237
CROOKE ET AL., J. PHARMACOL. EXP. THER., vol. 277, 1996, pages 923 - 937
WHAT IS CLAIMED IS: 1. An antisense oligonucleotide comprising 8-50 nucleotides, wherein the antisense oligonucleotide is capable of binding to, and forming a double- stranded structure with, a target sequence in a mRNA of an anti-fibrosis gene, wherein the target sequence is located in a non-coding strand of a double-stranded stem structure downstream of, and adjacent to, a uORF start codon in the mRNA, and wherein the binding of the antisense oligonucleotide to the target sequence disrupts the double-stranded stem structure of the uORF and enhances translation of a mORF of the mRNA. 2. The antisense oligonucleotide of claim 1, wherein the antisense oligonucleotide comprises one or more modified nucleotides. 3. The antisense oligonucleotide of claim 2, wherein the modified nucleotides comprise one or more modified sugar moiety and/or one or more modified internucleoside linkages. 4. The antisense oligonucleotide of any one of claims 1 to 3, wherein the anti-fibrosis gene is selected from the group consisting of GATA4, MEF2C, NKX2-5, TBX5, HNF4α, CRYAB, TCF21 and MYBPC3. 5. The antisense oligonucleotide of claim 4, wherein the cardiac fibrosis-related gene is GATA4. 6. The antisense oligonucleotide of claim 5, wherein the target sequence comprises the nucleotide sequence of SEQ ID NO:27. 7. The antisense oligonucleotide of any one of claims 1 to 6, wherein the antisense oligonucleotide is RNA. 8. The antisense oligonucleotide of claim 1, comprising SEQ ID NO:8. 9. An antisense oligonucleotide comprising 8-50 nucleotides, wherein the antisense oligonucleotide is capable of binding to, and forming a double- stranded structure with, a target sequence in a mRNA of an anti-fibrosis gene, wherein the target sequence is located downstream of, and adjacent to, a mORF start codon in the mRNA, and wherein the binding of the antisense oligonucleotide to the target sequence enhances translation from the mORF start codon. 10. The antisense oligonucleotide of claim 9, wherein the antisense oligonucleotide comprises one or more modified nucleotides. 11. The antisense oligonucleotide of claim 9, wherein the modified nucleotides comprise one or more modified sugar moiety and/or one or more modified internucleoside linkages. 12. The antisense oligonucleotide of any one of claims 9 to 11, wherein the anti- fibrosis gene is selected from the group consisting of GATA4, MEF2C, NKX2-5, TBX5, HNF4α, CRYAB, TCF21 and MYBPC3. 13. The antisense oligonucleotide of claim 12, wherein the target sequence comprises SEQ ID NO:28. 14. The antisense oligonucleotide of claim 12, wherein the target sequence comprises SEQ ID NO:29. 15. The antisense oligonucleotide of claim 12, wherein the target sequence comprises SEQ ID NO:30. 16. The antisense oligonucleotide of claim 12, wherein the target sequence comprises SEQ ID NO:47. 17. The antisense oligonucleotide of claim 12, wherein the target sequence comprises SEQ ID NO:48. 18. The antisense oligonucleotide of any one of claims 9 to 17, wherein the antisense oligonucleotide is RNA 19. The antisense oligonucleotide of claim 12, comprising SEQ ID NO:9 or 10. 20. The antisense oligonucleotide of claim 12, comprising SEQ ID NO:15. 21. The antisense oligonucleotide of claim 12, comprising SEQ ID NO:21. 22. The antisense oligonucleotide of claim 12, comprising SEQ ID NO:45. 23. The antisense oligonucleotide of claim 12, comprising SEQ ID NO:46. 24. An antisense oligonucleotide comprising 8-50 nucleotides, wherein the antisense oligonucleotide is capable of binding to, and forming a double- stranded structure with, a target sequence in a mRNA of a pro-fibrosis gene, wherein the target sequence is located downstream of, and adjacent to, an uORF start codon in the mRNA, and wherein the binding of the antisense oligonucleotide to the target sequence reduces translation from the mORF start codon. 25. The antisense oligonucleotide of claim 24, wherein the antisense oligonucleotide comprises one or more modified nucleotides. 26. The antisense oligonucleotide of claim 25, wherein the modified nucleotides comprise one or more modified sugar moiety and/or one or more modified internucleoside linkages. 27. The antisense oligonucleotide of any one of claims 24 to 26, wherein the pro- fibrosis gene is selected from the group consisting of eIF4G2, EPRS and MEOX1. 28. The antisense oligonucleotide of claim 27, wherein the target sequence comprises SEQ ID NO:31. 29. The antisense oligonucleotide of any one of claims 24 to 28, wherein the antisense oligonucleotide is RNA 30. The antisense oligonucleotide of claim 24, comprising SEQ ID NO:17. 31. An antisense oligonucleotide comprising 8-50 nucleotides, wherein the antisense oligonucleotide is a gapmer capable of binding to, and forming a double-stranded structure with, a target sequence in a mRNA of a pro-fibrosis gene, wherein the target sequence is located in a region that spans from 55 nucleotides upstream to 55 nucleotides downstream of an uORF start codon in the mRNA, and wherein the binding of the antisense oligonucleotide to the target sequence reduces translation from the mORF start codon and degrade the target mRNA. 32. The antisense oligonucleotide of claim 31, wherein the antisense oligonucleotide comprises one or more modified nucleotides. 33. The antisense oligonucleotide of claim 32, wherein the modified nucleotides comprise one or more modified sugar moiety and/or one or more modified internucleoside linkages. 34. The antisense oligonucleotide of any one of claims 31 to 33, wherein the pro- fibrosis gene is selected from the group consisting of eIF4G2, EPRS and MEOX1. 35. The antisense oligonucleotide of claim 34, wherein the target sequence comprises SEQ ID NO:49. 36. The antisense oligonucleotide of claim 35, comprising SEQ ID NO:41. 37. A pharmaceutical composition for anti-fibrosis therapy, comprising: the antisense oligonucleotide of any one of claims 1-36; and a pharmaceutically acceptable carrier. 38. A method for treating cardiac fibrosis, comprising administering in a subject in need thereof, an effective amount of the antisense oligonucleotide of any one of claims 1-36 or an effective amount of the pharmaceutical composition of claim 37. |
[0132] In some embodiments, the target sequence comprises the nucleotide sequence 5’-gcctgagccggggaag-3’ human MYBPC3 type II motASO target sequence, SEQ ID NO:47. [0133] In some embodiments, the target sequence comprises the nucleotide sequence 5’-ggacatcgccatccac-3’ human CRYAB type II motASO target sequence, SEQ ID NO:48. [0134] In some embodiments, the target sequence comprises human GATA4 mRNA sequence of SEQ ID NO:28. [0135] In some embodiments, the target sequence comprises human MEF2C mRNA sequence of SEQ ID NO:29. [0136] In some embodiments, the target sequence comprises human NKX2-5 mRNA sequence of SEQ ID NO:30. [0137] In some embodiments, the ASO comprises a sequence that is at least 50 %, 60%, 70%, 80% or 90% complementary to the target sequence. In some embodiments, the ASO comprises a sequence that is 100% complementary to the target sequence. In some embodiments, the ASO further comprises one or more modified nucleotide and/or modified internucleotide linkage. [0138] In some embodiments, the ASO is a human MYBPC3 type II motASO comprising SEQ ID NO:45. [0139] In some embodiments, the ASO is a human CRYAB type II motASO comprising SEQ ID NO:46. [0140] In some embodiments, the ASO is a human GATA4 type II motASO comprising SEQ ID NO:9 or SEQ ID NO:10. [0141] In some embodiments, the ASO is a human NKX2-5 type II motASO comprising SEQ ID NO:15. [0142] In some embodiments, the ASO is a human MEF2C type II motASO comprising SEQ ID NO:21. [0143] In some embodiments, the 5’ end of the ASO binds to a nucleotide position between +3 to +19 relative to the AUG start codon of the mORF, where +1 corresponds to the adenine in the AUG start codon. In some embodiments, the 3’ end of the ASO includes at least one nucleotide complementary to a nucleotide within the mORF start codon. In certain embodiments, the 3’ end of the ASO includes a cytosine, which is complementary to the guanine in the AUG start codon. ASOs reducing expression of pro-fibrosis gene products [0144] In some embodiments, the ASO is capable of forming a double-stranded structure with a target sequence downstream of, and adjacent to, a start codon of a uORF in the mRNA of a pro-fibrosis gene and inhibits mORF translation of the pro-fibrosis gene. (type II uotASO) In some embodiments, the target region includes regions that are two to eight nucleotides away from the adenine (A) of the uORF AUG start codon. [0145] In some embodiments, the pro-fibrosis gene is eIF4G2, EPRS or MEOX1. [0146] In some embodiments, the pro-fibrosis gene is eIF4G2, which is an essential fibrotic-stress mediator for extracellular matrix (ECM) mRNAs translation. Genetic knockout of eIF4G2 in cardiac myofibroblasts (Postn MCM ) attenuates cardiac dysfunction, pathological hypertrophy and fibrosis. The TGFβ-eIF4G2-IGFBP7 axis is a novel translation regulatory pathway mediating cardiac fibroblast activation and plays a key role in cardiac fibrosis. It has been shown that genetic knockout of eIF4G2 in cardiomyocytes (Myh6 MCM ) does not cause severe heart disease within 5 months. [0147] In some embodiments, the target sequence comprises human EIF4G2 mRNA sequence of SEQ ID NO:31. [0148] In some embodiments, the ASO comprises a sequence that is at least 50%, 60%, 70%, 80% or 90% complementary to the target sequence. In some embodiments, the ASO comprises a sequence that is 100% complementary to the target sequence. In some embodiments, the ASO further comprise one or more modified nucleotide and/or modified internucleotide linkage. [0149] In some embodiments, the 5’ end of the ASO binds to a nucleotide position between +3 to +19 relative to the AUG start codon of the uORF, where +1 corresponds to the adenine in the AUG start codon. In some embodiments, the 3’ end of the ASO includes at least one nucleotide complementary to a nucleotide within the uORF start codon. In certain embodiments, the 3’ end of the ASO includes a cytosine, which is complementary to the guanine in the AUG start codon. [0150] In some embodiments, the ASO is a human EIF4G2 type II uotASO comprising SEQ ID NO:17. [0151] In some embodiments, the ASO is a 5’-UTR-targeting gapmer ASO that targets the 5’-UTR of the mRNA of a pro-fibrosis gene. In some embodiments, 5’-UTR- targeting gapmer ASO is capable of binding to a target located in a region that spans from 55 nucleotides upstream to 55 nucleotides downstream of an uORF start codon in the mRNA. In some embodiments, 5’-UTR-targeting gapmer ASO is capable of binding to a target located in a region that spans from 45 nucleotides upstream to 45 nucleotides downstream of an uORF start codon in the mRNA. In some embodiments, 5’-UTR-targeting gapmer ASO is capable of binding to a target located in a region that spans from 35 nucleotides upstream to 35 nucleotides downstream of an uORF start codon in the mRNA. In some embodiments, 5’- UTR-targeting gapmer ASO is capable of binding to a target located in a region that spans from 25 nucleotides upstream to 25 nucleotides downstream of an uORF start codon in the mRNA. In some embodiments, 5’-UTR-targeting gapmer ASO is capable of binding to a target located in a region that spans from 15 nucleotides upstream to 15 nucleotides downstream of an uORF start codon in the mRNA. [0152] In some embodiments, the 5’-UTR-targeting gapmer ASO comprises a sequence that is at least 50%, 60%, 70%, 80% or 90% complementary to the target sequence. In some embodiments, the 5’-UTR-targeting gapmer ASO comprises a sequence that is 100% complementary to the target sequence. [0153] In some embodiments, the 5’-UTR-targeting gapmer ASO targets the 5’-UTR of the mRNA of human eIF4G2 gene. In some embodiments, the 5’-UTR-targeting gapmer ASO has a gap region of 5-20 nucleotides, flanked by two wing regions of 3-10 nucleotides. In some embodiments, the 5’-UTR-targeting gapmer ASO has a gap region of 10 nucleotides, flanked by two wing regions of 5 nucleotides. [0154] In some embodiments, the target sequence comprises human eIF4G2 mRNA sequence of SEQ ID NO:49. [0155] In some embodiments, the 5’-UTR-targeting gapmer ASO having a nucleotide sequence of SEQ ID NO:41. ASO Design Procedure [0156] Step 1. Determine the dominant alternative spliced mRNA isoform in the organ as ASO target. [0157] Step 2. Examine multiple parameters for ASO design, including 5’ UTR length, uORF presence, 5’ UTR GC content, dsRNA element, KOZAK sequence around uORF and mORF start codons, and effects from dsRNA-binding protein or RNA helicase. [0158] Step 3. Mechanism-based screen of ASOs: (1) Target uORF start codon using Type I uotASO that inhibits uORF while enhancing mORF translation; (2) Target mORF start codon using Class II motASO that directly enhances mORF translation. [0159] Step 4 (Target-to-Hit). Perform a tiling screen by shifting the ASO from initial ASO to target 3-nt (and then 1-nt) upstream or downstream regions. [0160] Step 5 (Hit-to-Lead). Optimal ASO identified for in vivo testing in animal model after validation of ASO effects in human cell lines and primary mouse cells. [0161] Exemplary embodiments of design strategies and sequences for MYBPC3 and CRYAB targets are shown in the below table for mORF-activating Type II motASO.
[0162] In some embodiments, the ASOs of the present application (e.g., Type I uotASOs, Type II uotASOs, Type II motASOs and 5’-UTR-targeting gapmer ASOs) have a length between 8 to 50, 8 to 40, 8 to 30, 8 to 25, 8 to 20, 8 to 16, 8 to 12, 10 to 50, 10 to 40, 10 to 30, 10 to 25, 10 to 20, 10 to 16, 10 to 12, 12 to 50, 12 to 40, 12 to 30, 12 to 25, 12 to 20, 12 to 16, 15 to 50, 15 to 40, 15 to 30, 15 to 25, 15 to 20, 20 to 50, 20 to 40, 20 to 30, or 20 to 25 nucleotides. Modified Nucleosides [0163] ASOs of the present application may comprise or consist of oligonucleotides comprising at least one modified nucleoside. Such modified nucleosides may comprise a modified sugar moiety, a modified nucleobase, or both. In some embodiments, the ASO comprises at least 5, at least 10, at least 15, at least 20, at least 25 or more modified nucleosides relative to the total number of nucleosides in the ASO. In some embodiments, the modified ASO includes a modified region of at least 5, at least 10, at least 15, at least 20, at least 25 or more contiguous modified nucleosides in the ASO. In some embodiments, each of the nucleosides in the ASO is modified. [0164] In certain preferred embodiments, the one or more modified nucleotides include a 2’-O-methyl modified sugar moiety and/or a modified internucleoside linkage. In some embodiments, the modified internucleoside linkage is a phosphodiester internucleoside linkage or a phosphorothioate internucleoside linkage. [0165] In some embodiments, the ASO of the present application comprises one or more sugar-modified nucleotides. In some embodiments, the ASO comprises the nucleotide sequence of any one of SEQ ID NOs:3-6 with one or more modified sugar moieties and/or modified internucleoside linkages. [0166] In certain particular embodiments, the ASO comprises the nucleotide sequence of AmoCmoGmoUmoAmoUmoUmoAmoAmoAmoUmoCmoCmoAmoGmoCm (SEQ ID NO:7), or AmoCmoGmoAmoAmoUmoUmoAmoAmoAmoUmoCmoCmoAmoGmoCm (SEQ ID NO:8), CmoUmoUmoCmoCmoCmoCmoGmoGmoCmoUmoCmoAmoGmoGmoCm (SEQ ID NO:45) or GmoUmoGmoGmoAmoUmoGmoGmoCmoGmoAmoUmoGmoUmoCmoCm (SEQ ID NO:46) where “m” indicates a 2’-O-methyl modification, and “o” indicates a phosphodiester or phosphorothioate internucleoside linkage. It should be noted that in any of the sequences disclosed in the present application, where the modifications “o” or “mo” are included, such modifications may be substituted with any nucleoside modifications described herein or they may contain no nucleoside modifications at all. [0167] In certain particular embodiments, the ASO comprises the nucleotide sequence of GesCesCesAesCesCdsTdsCdsCdsAdsTdsAdsGdsAdsGdsCesUesCesCesGe (SEQ ID NPO:41), wherein “e” indicates 2’-O-methoxyethyl (MOE) modification, “s” indicates a phosphorothioate internucleoside linkage, and “d” indicates DNA. Sugar moieties [0168] The ASOs of the present application may contain nucleosides with naturally occurring sugar moieties and/or nucleosides with modified sugar moieties. ASOs comprising nucleosides with modified sugar moieties may have desirable properties, such as enhanced nuclease stability or increased binding affinity with a target nucleic acid relative to ASOs comprising only nucleosides comprising naturally occurring sugar moieties. In some embodiments, the modified sugar moieties are substituted sugar moieties. In certain embodiments, the modified sugar moieties are bicyclic or tricyclic sugar moieties. In certain embodiments, the modified sugar moieties are sugar surrogates. Such sugar surrogates may include one or more substitutions corresponding to those of substituted sugar moieties. [0169] In certain embodiments, the modified sugar moieties are substituted sugar moieties comprising one or more substituent, including but not limited to substituents at the 2′ and/or 5′ positions. Examples of sugar substituents suitable for the 2′-position, include, but are not limited to: 2′-F, 2′-OCH 3 (“O-methyl”), and 2′-O(CH 2 ) 2 OCH 3 . In certain embodiments, sugar substituents at the 2′ position is selected from allyl, amino, azido, thio, O-allyl, O—C1-C10 alkyl, O—C1-C10 substituted alkyl; O—C1-C10 alkoxy; O—C1-C10 substituted alkoxy, OCF 3 , O(CH 2 ) 2 SCH 3 , O(CH 2 ) 2 —O—N(Rm)(Rn), and O—CH 2 — C(═O)—N(Rm)(Rn), where each Rm and Rn is, independently, H or substituted or unsubstituted C1-C10 alkyl. Examples of sugar substituents at the 5′-position, include, but are not limited to: 5′-methyl (R or S); 5′-vinyl, and 5′-methoxy. In certain embodiments, substituted sugars comprise more than one non-bridging sugar substituent, for example, 2′-F- 5′-methyl sugar moieties (see, e.g., PCT International Application WO 2008/101157, for additional 5′,2′-bis substituted sugar moieties and nucleosides). [0170] Nucleosides comprising 2′-substituted sugar moieties are referred to as 2′- substituted nucleosides. In certain embodiments, a 2′-substituted nucleoside comprises a 2′- substituent group selected from halo, allyl, amino, azido, O—C1-C10 alkoxy; O—C1-C10 substituted alkoxy, SH, CN, OCN, CF 3 , OCF 3 , O-alkyl, S-alkyl, N(Rm)-alkyl; O-alkenyl, S- alkenyl, or N(Rm)-alkenyl; O-alkynyl, S-alkynyl, N(Rm)-alkynyl; O-alkylenyl-O-alkyl, alkynyl, alkaryl, aralkyl, O-alkaryl, O-aralkyl, O(CH 2 ) 2 SCH 3 , O—(CH 2 ) 2 —O—N(Rm)(Rn) or O—CH 2 —C(═O)—N(Rm)(Rn), where each Rm and Rn is, independently, H, an amino protecting group or substituted or unsubstituted C1-C10 alkyl. These 2′-substituent groups can be further substituted with one or more substituent groups independently selected from hydroxyl, amino, alkoxy, carboxy, benzyl, phenyl, nitro (NO2), thiol, thioalkoxy (S-alkyl), halogen, alkyl, aryl, alkenyl and alkynyl. [0171] In certain embodiments, a 2′-substituted nucleoside comprises a 2′-substituent group selected from F, NH 2 , N 3 , OCF 3 , O—CH 3 , O(CH 2 ) 3 NH 2 , CH 2 —CH═CH 2 , O—CH 2 — CH═CH 2 , OCH 2 CH 2 OCH 3 , O(CH 2 ) 2 SCH 3 , O—(CH 2 ) 2 —O—N(Rm)(Rn), O(CH 2 ) 2 O(CH 2 ) 2 N(CH 3 ) 2 , and N-substituted acetamide (O—CH 2 —C(═O)—N(Rm)(Rn) where each Rm and Rn is, independently, H, an amino protecting group or substituted or unsubstituted C1-C10 alkyl. [0172] In certain embodiments, a 2′-substituted nucleoside comprises a sugar moiety comprising a 2′-substituent group selected from F, OCF 3 , O—CH 3 , OCH 2 CH 2 OCH 3 , O(CH 2 ) 2 SCH 3 , O—(CH 2 ) 2 —O—N(CH 3 ) 2 , —O(CH 2 ) 2 O(CH 2 ) 2 N(CH 3 ) 2 , and O—CH 2 — C(═O)—N(H)CH 3 . [0173] Certain modified sugar moieties comprise a bridging sugar substituent that forms a second ring resulting in a bicyclic sugar moiety. In certain such embodiments, the bicyclic sugar moiety comprises a bridge between the 4′ and the 2′ furanose ring atoms. Examples of such 4′ to 2′ sugar substituents, include, but are not limited to: — [C(Ra)(Rb)]n—, —[C(Ra)(Rb)]n—O—, —C(RaRb)—N(R)—O— or, —C(RaRb)—O— N(R)—; 4′-CH 2 -2′, 4′-(CH 2 ) 2 -2′, 4′-(CH 2 ) 3 -2′, 4′-(CH 2 )—O-2′ (LNA); 4′-(CH 2 )—S-2; 4′- (CH 2 ) 2 —O-2′ (ENA); 4′-CH(CH 3 )—O-2′ (cEt) and 4′-CH(CH 2 OCH 3 )—O-2′, and analogs thereof (see, e.g., U.S. Pat. No.7,399,845, issued on Jul.15, 2008); 4′-C(CH 3 )(CH 3 )—O-2′ and analogs thereof, (see, e.g., WO2009/006478, published Jan.8, 2009); 4′-CH 2 —N(OCH 3 )- 2′ and analogs thereof (see, e.g., WO2008/150729, published Dec.11, 2008); 4′-CH 2 —O— N(CH 3 )-2′ (see, e.g., US2004/0171570, published Sep.2, 2004); 4′-CH 2 —O—N(R)-2′, and 4′-CH 2 —N(R)-0-2′-, wherein each R is, independently, H, a protecting group, or C1-C12 alkyl; 4′-CH 2 —N(R)—O-2′, wherein R is H, C1-C12 alkyl, or a protecting group (see, U.S. Pat. No.7,427,672, issued on Sep.23, 2008); 4′-CH 2 —C(H)(CH 3 )-2′ (see, e.g., Chattopadhyaya, et al., J. Org. Chem., 2009, 74, 118-134); and 4′-CH 2 —C(═CH 2 )-2′ and analogs thereof (see, published PCT International Application WO 2008/154401, published on Dec.8, 2008). [0174] In certain embodiments, such 4′ to 2′ bridges independently comprise from 1 to 4 linked groups independently selected from —[C(Ra)(Rb)]n—, —C(Ra)═C(Rb)—, — C(Ra)═N—, —C(═NRa)—, —C(═O)—, —C(═S)—, —O—, —Si(Ra) 2 —, —S(═O)x—, and —N(Ra)—; wherein: x is 0, 1, or 2; n is 1, 2, 3, or 4; each Ra and Rb is, independently, H, a protecting group, hydroxyl, C1-C12 alkyl, substituted C1-C12 alkyl, C2-C12 alkenyl, substituted C2-C12 alkenyl, C2-C12 alkynyl, substituted C2-C12 alkynyl, C5-C20 aryl, substituted C5-C20 aryl, heterocycle radical, substituted heterocycle radical, heteroaryl, substituted heteroaryl, C5-C7 alicyclic radical, substituted C5-C7 alicyclic radical, halogen, OJ1, NJ1J2, SJ1, N3, COOJ1, acyl (C(═O)— H), substituted acyl, CN, sulfonyl (S(═O)2-J1), or sulfoxyl (S(═O)-J1); and each J1 and J2 is, independently, H, C1-C12 alkyl, substituted C1-C12 alkyl, C2-C12 alkenyl, substituted C2- C12 alkenyl, C2-C12 alkynyl, substituted C2-C12 alkynyl, C5-C20 aryl, substituted C5-C20 aryl, acyl (C(═O)—H), substituted acyl, a heterocycle radical, a substituted heterocycle radical, C1-C12 aminoalkyl, substituted C1-C12 aminoalkyl, or a protecting group. [0175] Nucleosides comprising bicyclic sugar moieties are referred to as bicyclic nucleosides or BNAs. Bicyclic nucleosides include, but are not limited to, (A) α-L- Methyleneoxy (4′-CH 2 —O-2′) BNA, (B) β-D-Methyleneoxy (4′-CH 2 —O-2′) BNA (also referred to as locked nucleic acid or LNA), (C) Ethyleneoxy (4′-(CH 2 ) 2 —O-2′) BNA, (D) Aminooxy (4′-CH 2 —O—N(R)-2′) BNA, (E) Oxyamino (4′-CH 2 —N(R)—O-2′) BNA, (F) Methyl(methyleneoxy) (4′-CH(CH 3 )—O-2′) BNA (also referred to as constrained ethyl or cEt), (G) methylene-thio(4′-CH 2 —S-2′) BNA, (H) methylene-amino (4′-CH 2 -N(R)-2′) BNA, (I) methyl carbocyclic (4′-CH 2 —CH(CH 3 )-2′) BNA, (J) propylene carbocyclic (4′-(CH 2 ) 3 -2′) BNA, and (M) 4′-CH 2 —O—CH 2 -2′ as depicted below.
wherein Bx is a nucleobase moiety and R is, independently, H, a protecting group, or C1-C12 alkyl. [0176] Additional bicyclic sugar moieties are known in the art, for example: Singh et al., Chem. Commun.,1998, 4, 455-456; Koshkin et al., Tetrahedron, 1998, 54, 3607-3630; Wahlestedt et al., Proc. Natl. Acad. Sci. U.S.A, 2000, 97, 5633-5638; Kumar et al., Bioorg. Med. Chem. Lett., 1998, 8, 2219-2222; Singh et al., J. Org. Chem., 1998, 63, 10035-10039; Srivastava et al., J. Am. Chem. Soc.,129(26) 8362-8379 (Jul.4, 2007); Elayadi et al., Curr. Opinion Invens. Drugs, 2001, 2, 558-561; Braasch et al., Chem. Biol., 2001, 8, 1-7; Orum et al., Curr. Opinion Mol. Ther., 2001, 3, 239-243; U.S. Pat. Nos.7,053,207, 6,268,490, 6,770,748, 6,794,499, 7,034,133, 6,525,191, 6,670,461, and 7,399,845; WO 2004/106356, WO 1994/14226, WO 2005/021570, and WO 2007/134181; U.S. Patent Publication Nos. US2004/0171570, US2007/0287831, and US2008/0039618; U.S. patent Ser. Nos. 12/129,154, 60/989,574, 61/026,995, 61/026,998, 61/056,564, 61/086,231, 61/097,787, and 61/099,844; and PCT International Applications Nos. PCT/US2008/064591, PCT/US2008/066154, and PCT/US2008/068922. [0177] In certain embodiments, bicyclic sugar moieties and nucleosides incorporating such bicyclic sugar moieties are further defined by isomeric configuration. For example, a nucleoside comprising a 4′-2′ methylene-oxy bridge, may be in the α-L configuration or in the β-D configuration. Previously, α-L-methyleneoxy (4′-CH2—O-2′) bicyclic nucleosides have been incorporated into antisense oligonucleotides that showed antisense activity (Frieden et al., Nucleic Acids Research, 2003, 21, 6365-6372). [0178] In certain embodiments, substituted sugar moieties comprise one or more non- bridging sugar substituent and one or more bridging sugar substituent (e.g., 5′-substituted and 4′-2′ bridged sugars). (see, PCT International Application WO 2007/134181, published on Nov.22, 2007, wherein LNA is substituted with, for example, a 5′-methyl or a 5′-vinyl group). [0179] In certain embodiments, modified sugar moieties are sugar surrogates. In certain such embodiments, the oxygen atom of the naturally occurring sugar is substituted, e.g., with a sulfer, carbon or nitrogen atom. In certain such embodiments, such modified sugar moiety also comprises bridging and/or non-bridging substituents as described above. For example, certain sugar surrogates comprise a 4′-sulfer atom and a substitution at the 2′- position (see, e.g., published U.S. Patent Application US2005/0130923, published on Jun.16, 2005) and/or the 5′ position. By way of additional example, carbocyclic bicyclic nucleosides having a 4′-2′ bridge have been described (see, e.g., Freier et al., Nucleic Acids Research, 1997, 25(22), 4429-4443 and Albaek et al., J. Org. Chem., 2006, 71, 7731-7740). [0180] In certain embodiments, sugar surrogates comprise rings having other than 5- atoms. For example, in certain embodiments, a sugar surrogate comprises a six-membered tetrahydropyran. Such tetrahydropyrans may be further modified or substituted. Nucleosides comprising such modified tetrahydropyrans include, but are not limited to, hexitol nucleic acid (HNA), anitol nucleic acid (ANA), 4amanti nucleic acid (MNA) (see Leumann, C J. Bioorg. & Med. Chem. (2002) 10:841-854), fluoro HNA (F-HNA), and those compounds having Formula VII: wherein independently for each of said at least one tetrahydropyran nucleoside analog of Formula VII: Bx is a nucleobase moiety; T3 and T4 are each, independently, an internucleoside linking group linking the tetrahydropyran nucleoside analog to the antisense oligonucleotide or one of T3 and T4 is an internucleoside linking group linking the tetrahydropyran nucleoside analog to the antisense oligonucleotide and the other of T3 and T4 is H, a hydroxyl protecting group, a linked conjugate group, or a 5′ or 3′-terminal group; q1, q2, q3, q4, q5, q6 and q7 are each, independently, H, C1-C6 alkyl, substituted C1- C6 alkyl, C2-C6 alkenyl, substituted C2-C6 alkenyl, C2-C6 alkynyl, or substituted C2-C6 alkynyl; and each of R1 and R2 is independently selected from among: hydrogen, halogen, substituted or unsubstituted alkoxy, NJ1J2, SJ1, N3, OC(═X)J1, OC(═X)NJ1J2, NJ3C(═X)NJ1J2, and CN, wherein X is O, S or NJ1, and each J1, J2, and J3 is, independently, H or C1-C6 alkyl. [0181] In certain embodiments, the modified THP nucleosides of Formula VII are provided wherein q1, q2, q3, q4, q5, q6 and q7 are each H. In certain embodiments, at least one of q1, q2, q3, q4, q5, q6 and q7 is other than H. In certain embodiments, at least one of q1, q2, q3, q4, q5, q6 and q7 is methyl. In certain embodiments, THP nucleosides of Formula VII are provided wherein one of R1 and R2 is F. In certain embodiments, R1 is fluoro and R2 is H, R1 is methoxy and R2 is H, and R1 is methoxyethoxy and R2 is H. [0182] Many other bicyclic and tricyclic sugar and sugar surrogate ring systems are known in the art that can be used to modify nucleosides (see, e.g., review article: Leumann, J C, Bioorganic & Medicinal Chemistry, 2002, 10, 841-854). [0183] In certain embodiments, sugar surrogates comprise rings having more than 5 atoms and more than one heteroatom. For example, nucleosides comprising morpholino sugar moieties and their use in oligomeric compounds has been reported (see for example: Braasch et al., Biochemistry, 2002, 41, 4503-4510; and U.S. Pat. Nos.5,698,685; 5,166,315; 5,185,444; and 5,034,506). As used here, the term “morpholino” means a sugar surrogate having the following structure:
[0184] In certain embodiments, morpholinos may be modified, for example by adding or altering various substituent groups from the above morpholino structure. Such sugar surrogates are referred to herein as “modified morpholinos.” [0185] Combinations of modifications are also provided without limitation, such as 2′-F-5′-methyl substituted nucleosides (see PCT International Application WO 2008/101157 Published on Aug.21, 2008 for other disclosed 5′,2′-bis substituted nucleosides) and replacement of the ribosyl ring oxygen atom with S and further substitution at the 2′-position (see published U.S. Patent Application US2005-0130923, published on Jun.16, 2005) or alternatively 5′-substitution of a bicyclic nucleic acid (see PCT International Application WO 2007/134181, published on Nov.22, 2007 wherein a 4′-CH 2 —O-2′ bicyclic nucleoside is further substituted at the 5′ position with a 5′-methyl or a 5′-vinyl group). The synthesis and preparation of carbocyclic bicyclic nucleosides along with their oligomerization and biochemical studies have also been described (see, e.g., Srivastava et al., J. Am. Chem. Soc. 2007, 129(26), 8362-8379). Modified Nucleobases [0186] In certain embodiments, nucleosides of the present invention comprise one or more unmodified nucleobases. In certain embodiments, nucleosides of the present invention comprise one or more modified nucleobases. [0187] In certain embodiments, modified nucleobases are selected from: universal bases, hydrophobic bases, promiscuous bases, size-expanded bases, and fluorinated bases as defined herein.5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and O-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil; 5-propynylcytosine; 5- hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5- propynyl (—C≡C—CH 3 ) uracil and cytosine and other alkynyl derivatives of pyrimidine bases, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8- amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7- methylguanine and 7-methyladenine, 2-F-adenine, 2-amino-adenine, 8-azaguanine and 8- azaadenine, 7-deazaguanine and 7-deazaadenine, 3-deazaguanine and 3-deazaadenine, universal bases, hydrophobic bases, promiscuous bases, size-expanded bases, and fluorinated bases as defined herein. Further modified nucleobases include tricyclic pyrimidines such as phenoxazine cytidine([5,4-b][1,4]benzoxazin-2(3H)-one), phenothiazine cytidine (1H- pyrimido[5,4-b][1,4]benzothiazin-2(3H)-one), G-clamps such as a substituted phenoxazine cytidine (e.g.9-(2-aminoethoxy)-H-pyrimido[5,4-b][1,4]benzoxazin-2(3H )-one), carbazole cytidine (2H-pyrimido[4,5-b]indol-2-one), pyridoindole cytidine (H- pyrido[3′,2′:4,5]pyrrolo[2,3-d]pyrimidin-2-one). Modified nucleobases may also include those in which the purine or pyrimidine base is replaced with other heterocycles, for example 7-deaza-adenine, 7-deazaguanosine, 2-aminopyridine and 2-pyridone. Further nucleobases include those disclosed in U.S. Pat. No.3,687,808, those disclosed in The Concise Encyclopedia Of Polymer Science And Engineering, Kroschwitz, J. I., Ed., John Wiley & Sons, 1990, 858-859; those disclosed by Englisch et al., Angewandte Chemie, International Edition, 1991, 30, 613; and those disclosed by Sanghvi, Y. S., Chapter 15, Antisense Research and Applications, Crooke, S. T. and Lebleu, B., Eds., CRC Press, 1993, 273-288. [0188] Representative United States patents that teach the preparation of certain of the above noted modified nucleobases as well as other modified nucleobases include without limitation, U.S. Pat. Nos.3,687,808; 4,845,205; 5,130,302; 5,134,066; 5,175,273; 5,367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908; 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,594,121; 5,596,091; 5,614,617; 5,645,985; 5,681,941; 5,750,692; 5,763,588; 5,830,653 and 6,005,096, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference in its entirety. Internucleoside Linkages [0189] In certain embodiments, nucleosides may be linked together using any internucleoside linkage to form oligonucleotides. The two main classes of internucleoside linking groups are defined by the presence or absence of a phosphorus atom. Representative phosphorus containing internucleoside linkages include, but are not limited to, phosphodiesters (P═O), phosphotriesters, methylphosphonates, phosphoramidate, and phosphorothioates (P═S). Representative non-phosphorus containing internucleoside linking groups include, but are not limited to, methylenemethylimino (—CH 2 —N(CH 3 )—O—CH 2 — ), thiodiester (—O—C(O)—S—), thionocarbamate (—O—C(O)(NH)—S—); siloxane (— O—Si(H) 2 —O—); and N,N′-dimethylhydrazine (—CH 2 —N(CH 3 )—N(CH 3 )—). Modified linkages, compared to natural phosphodiester linkages, can be used to alter, typically increase, nuclease resistance of the oligonucleotide. In certain embodiments, internucleoside linkages having a chiral atom can be prepared as a racemic mixture, or as separate enantiomers. Representative chiral linkages include, but are not limited to, alkylphosphonates and phosphorothioates. Methods of preparation of phosphorous-containing and non- phosphorous-containing internucleoside linkages are well known to those skilled in the art. [0190] The oligonucleotides described herein contain one or more asymmetric centers and thus give rise to enantiomers, diastereomers, and other stereoisomeric configurations that may be defined, in terms of absolute stereochemistry, as (R) or (S), α or β such as for sugar anomers, or as (D) or (L) such as for amino acids etc. Included in the antisense oligonucleotides provided herein are all such possible isomers, as well as their racemic and optically pure forms. [0191] Neutral internucleoside linkages include without limitation, phosphotriesters, methylphosphonates, MMI (3′-CH 2 —N(CH 3 )—O-5′), amide-3 (3′-CH 2 —C(═O)—N(H)-5′), amide-4 (3′-CH 2 —N(H)—C(═O)-5′), formacetal (3′-O—CH 2 —O-5′), and thioformacetal (3′- S—CH 2 —O-5′). Further neutral internucleoside linkages include nonionic linkages comprising siloxane (dialkylsiloxane), carboxylate ester, carboxamide, sulfide, sulfonate ester and amides (See for example: Carbohydrate Modifications in Antisense Research; Y. S. Sanghvi and P. D. Cook, Eds., ACS Symposium Series 580; Chapters 3 and 4, 40-65). Further neutral internucleoside linkages include nonionic linkages comprising mixed N, O, S and CH 2 component parts. Motifs [0192] In some embodiments, the ASO of the present application comprises a modified oligonucleotide. In some embodiments, the modified oligonucleotide comprises one or more modified sugars. In some embodiments, the modified oligonucleotide comprises one or more modified nucleobases. In some embodiments, the modified oligonucleotide comprises one or more modified internucleoside linkages. In some embodiments, the modifications (sugar modifications, nucleobase modifications, and/or linkage modifications) define a pattern or motif. In some embodiments, the patterns of chemical modifications of sugar moieties, internucleoside linkages, and nucleobases are each independent of one another. Thus, a modified oligonucleotide may be described by its sugar modification motif, internucleoside linkage motif and/or nucleobase modification motif (as used herein, nucleobase modification motif describes the chemical modifications to the nucleobases independent of the sequence of nucleobases). [0193] In certain embodiments, every sugar moiety of the modified oligonucleotides of the present invention is modified. In certain embodiments, modified oligonucleotides include one or more unmodified sugar moiety. Overall Lengths [0194] In certain embodiments, the present invention provides modified oligonucleotides of any of a variety of ranges of lengths. In certain embodiments, the invention provides oligomeric compounds or oligonucleotides consisting of X to Y linked nucleosides, where X represents the fewest number of nucleosides in the range and Y represents the largest number of nucleosides in the range. In certain such embodiments, X and Y are each independently selected from 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, and 50; provided that X≤Y. For example, in certain embodiments, the invention provides modified oligonucleotides which comprise oligonucleotides consisting of 5 to 6, 5 to 7, 5 to 8, 5 to 9, 5 to 5 to 10, 5 to 11, 5 to 12, 5 to 13, 5 to 14, 5 to 15, 5 to 16, 5 to 17, 5 to 18, 5 to 19, 5 to 20, 6 to 76 to 8, 6 to 9, 6 to 10, 6 to 11, 6 to 12, 6 to 13, 6 to 14, 6 to 15, 6 to 16, 6 to 17, 6 to 18, 6 to 19, 6 to 20, 7 to 8, 7 to 9, 7 to 10, 7 to 11, 7 to 12, 7 to 13, 7 to 14, 7 to 15, 7 to 16, 7 to 17, 7 to 18, 7 to 19, 7 to 20, 8 to 9, 8 to 10, 8 to 11, 8 to 12, 8 to 13, 8 to 14, 8 to 15, 8 to 16, 8 to 17, 8 to 18, 8 to 19, 8 to 20, 8 to 21, 8 to 22, 8 to 23, 8 to 24, 8 to 25, 8 to 26, 8 to 27, 8 to 28, 8 to 29, 8 to 30, 9 to 10, 9 to 11, 9 to 12, 9 to 13, 9 to 14, 9 to 15, 9 to 16, 9 to 17, 9 to 18, 9 to 19, 9 to 20, 9 to 21, 9 to 22, 9 to 23, 9 to 24, 9 to 25, 9 to 26, 9 to 27, 9 to 28, 9 to 29, 9 to 30, 10 to 11, 10 to 12, 10 to 13, 10 to 14, 10 to 15, 10 to 16, 10 to 17, 10 to 18, 10 to 19, 10 to 20, 10 to 21, 10 to 22, 10 to 23, 10 to 24, 10 to 25, 10 to 26, 10 to 27, 10 to 28, 10 to 29, 10 to 30, 11 to 12, 11 to 13, 11 to 14, 11 to 15, 11 to 16, 11 to 17, 11 to 18, 11 to 19, 11 to 20, 11 to 21, 11 to 22, 11 to 23, 11 to 24, 11 to 25, 11 to 26, 11 to 27, 11 to 28, 11 to 29, 11 to 30, 12 to 13, 12 to 14, 12 to 15, 12 to 16, 12 to 17, 12 to 18, 12 to 19, 12 to 20, 12 to 21, 12 to 22, 12 to 23, 12 to 24, 12 to 25, 12 to 26, 12 to 27, 12 to 28, 12 to 29, 12 to 30, 13 to 14, 13 to 15, 13 to 16, 13 to 17, 13 to 18, 13 to 19, 13 to 20, 13 to 21, 13 to 22, 13 to 23, 13 to 24, 13 to 25, 13 to 26, 13 to 27, 13 to 28, 13 to 29, 13 to 30, 14 to 15, 14 to 16, 14 to 17, 14 to 18, 14 to 19, 14 to 20, 14 to 21, 14 to 22, 14 to 23, 14 to 24, 14 to 25, 14 to 26, 14 to 27, 14 to 28, 14 to 29, 14 to 30, 15 to 16, 15 to 17, 15 to 18, 15 to 19, 15 to 20, 15 to 21, 15 to 22, 15 to 23, 15 to 24, 15 to 25, 15 to 26, 15 to 27, 15 to 28, 15 to 29, 15 to 30, 16 to 17, 16 to 18, 16 to 19, 16 to 20, 16 to 21, 16 to 22, 16 to 23, 16 to 24, 16 to 25, 16 to 26, 16 to 27, 16 to 28, 16 to 29, 16 to 30, 17 to 18, 17 to 19, 17 to 20, 17 to 21, 17 to 22, 17 to 23, 17 to 24, 17 to 25, 17 to 26, 17 to 27, 17 to 28, 17 to 29, 17 to 30, 18 to 19, 18 to 20, 18 to 21, 18 to 22, 18 to 23, 18 to 24, 18 to 25, 18 to 26, 18 to 27, 18 to 28, 18 to 29, 18 to 30, 19 to 20, 19 to 21, 19 to 22, 19 to 23, 19 to 24, 19 to 25, 19 to 26, 19 to 29, 19 to 28, 19 to 29, 19 to 30, 20 to 21, 20 to 22, 20 to 23, 20 to 24, 20 to 25, 20 to 26, 20 to 27, 20 to 28, 20 to 29, 20 to 30, 21 to 22, 21 to 23, 21 to 24, 21 to 25, 21 to 26, 21 to 27, 21 to 28, 21 to 29, 21 to 30, 22 to 23, 22 to 24, 22 to 25, 22 to 26, 22 to 27, 22 to 28, 22 to 29, 22 to 30, 23 to 24, 23 to 25, 23 to 26, 23 to 27, 23 to 28, 23 to 29, 23 to 30, 24 to 25, 24 to 26, 24 to 27, 24 to 28, 24 to 29, 24 to 30, 25 to 26, 25 to 27, 25 to 28, 25 to 29, 25 to 30, 26 to 27, 26 to 28, 26 to 29, 26 to 30, 27 to 28, 27 to 29, 27 to 30, 28 to 29, 28 to 30, or 29 to 30 linked nucleosides. In embodiments where the number of nucleosides of an oligomeric compound or oligonucleotide is limited, whether to a range or to a specific number, the oligomeric compound or oligonucleotide may, nonetheless further comprise additional other substituents. For example, an oligonucleotide comprising 8- 30 nucleosides excludes oligonucleotides having 31 nucleosides, but, unless otherwise indicated, such an oligonucleotide may further comprise, for example one or more conjugates, terminal groups, or other substituents. In certain embodiments, a modified oligonucleotide has any of the above lengths. [0195] Further, where an oligonucleotide is described by an overall length range and by regions having specified lengths, and where the sum of specified lengths of the regions is less than the upper limit of the overall length range, the oligonucleotide may have additional nucleosides, beyond those of the specified regions, provided that the total number of nucleosides does not exceed the upper limit of the overall length range. [0196] In certain embodiments, oligonucleotides of the present application are characterized by their modification motif and overall length. In certain embodiments, such parameters are each independent of one another. Oligomeric Compounds [0197] In certain embodiments, the invention provides oligomeric compounds, which consist of an oligonucleotide (modified or unmodified) and optionally one or more conjugate groups and/or terminal groups. Conjugate groups consist of one or more conjugate moiety and a conjugate linker which links the conjugate moiety to the oligonucleotide. Conjugate groups may be attached to either or both ends of an oligonucleotide and/or at any internal position. In certain embodiments, conjugate groups are attached to the 2′-position of a nucleoside of a modified oligonucleotide. In certain embodiments, conjugate groups that are attached to either or both ends of an oligonucleotide are terminal groups. In certain such embodiments, conjugate groups or terminal groups are attached at the 3′ and/or 5′-end of oligonucleotides. In certain such embodiments, conjugate groups (or terminal groups) are attached at the 3′-end of oligonucleotides. In certain embodiments, conjugate groups are attached near the 3′-end of oligonucleotides. In certain embodiments, conjugate groups (or terminal groups) are attached at the 5′-end of oligonucleotides. In certain embodiments, conjugate groups are attached near the 5′-end of oligonucleotides. [0198] Examples of terminal groups include but are not limited to conjugate groups, capping groups, phosphate moieties, protecting groups, abasic nucleosides, modified or unmodified nucleosides, and two or more nucleosides that are independently modified or unmodified. [0199] In certain embodiments, antisense oligonucleotides are provided wherein the 5’-terminal group comprises a 5’-terminal stabilized phosphate. A “5’-terminal stabilized phosphate” is a 5’-terminal phosphate group having one or more modifications that increase nuclease stability relative to a 5’-phosphate. [0200] In certain embodiments, antisense oligonucleotides are provided wherein the 5′-terminal group has Formula IIe: wherein: Bx is uracil, thymine, cytosine, 5-methyl cytosine, adenine or guanine; T2 is a phosphorothioate internucleoside linking group linking the compound of Formula Iie to the oligomeric compound; and G is halogen, OCH 3 , OCF 3 , OCH 2 CH 3 , OCH 2 CF 3 , OCH 2 -CH═CH 2 , O(CH 2 ) 2 -OCH 3 , O(CH 2 ) 2 -O(CH 2 ) 2 -N(CH 3 ) 2 , OCH 2 C(═O)—N(H)CH 3 , OCH 2 C(═O)—N(H)—(CH 2 ) 2 - N(CH 3 ) 2 or OCH 2 -N(H)—C(═NH)NH 2 . [0201] In certain embodiments, antisense oligonucleotides are provided wherein said 5′-terminal compound has Formula IIe wherein G is F, OCH 3 or O(CH 2 ) 2 -OCH 3 . [0202] In certain embodiments, the 5′-terminal group is a 5′-terminal stabilized phosphate comprising a vinyl phosphonate represented by Formula IIe above. Conjugate groups [0203] In certain embodiments, the ASO of the present application comprises an antisense oligonucleotide modified by covalent attachment of one or more conjugate groups (also referred to as “conjugate partner”). In general, conjugate groups modify one or more properties of the attached oligonucleotide including but not limited to pharmacodynamics, pharmacokinetics, stability, binding, absorption, cellular distribution, cellular uptake, charge and clearance. As used herein, “conjugate group” means a radical group comprising a group of atoms that are attached to an oligonucleotide or oligomeric compound. In general, conjugate groups modify one or more properties of the compound to which they are attached, including but not limited to, pharmacodynamics, pharmacokinetics, binding, absorption, cellular distribution, cellular uptake, charge and/or clearance properties. Conjugate groups are routinely used in the chemical arts and can include a conjugate linker that covalently links the conjugate group to an oligonucleotide or oligomeric compound. In certain embodiments, conjugate groups include a cleavable moiety that covalently links the conjugate group to an oligonucleotide or oligomeric compound. In certain embodiments, conjugate groups include a conjugate linker and a cleavable moiety to covalently link the conjugate group to an oligonucleotide or oligomeric compound. In certain embodiments, a conjugate group has the general formula: wherein n is from 1 to about 3, m is 0 when n is 1 or m is 1 when n is 2 or 3, j is 1 or 0, k is 1 or 0 and the sum of j and k is at least one. [0204] In certain embodiments, n is 1, j is 1 and k is 0. In certain embodiments, n is 1, j is 0 and k is 1. In certain embodiments, n is 1, j is 1 and k is 1. In certain embodiments, n is 2, j is 1 and k is 0. In certain embodiments, n is 2, j is 0 and k is 1. In certain embodiments, n is 2, j is 1 and k is 1. In certain embodiments, n is 3, j is 1 and k is 0. In certain embodiments, n is 3, j is 0 and k is 1. In certain embodiments, n is 3, j is 1 and k is 1. [0205] Conjugate groups are shown herein as radicals, providing a bond for forming covalent attachment to an oligomeric compound such as an oligonucleotide. In certain embodiments, the point of attachment on the oligomeric compound is at the 3′-terminal nucleoside or modified nucleoside. In certain embodiments, the point of attachment on the oligomeric compound is the 3′-oxygen atom of the 3′-hydroxyl group of the 3′ terminal nucleoside or modified nucleoside. In certain embodiments, the point of attachment on the oligomeric compound is at the 5′-terminal nucleoside or modified nucleoside. In certain embodiments the point of attachment on the oligomeric compound is the 5′-oxygen atom of the 5′-hydroxyl group of the 5′-terminal nucleoside or modified nucleoside. In certain embodiments, the point of attachment on the oligomeric compound is at any reactive site on a nucleoside, a modified nucleoside or an internucleoside linkage. [0206] As used herein, “cleavable moiety” and “cleavable bond” mean a cleavable bond or group of atoms that is capable of being split or cleaved under certain physiological conditions. In certain embodiments, a cleavable moiety is a cleavable bond. In certain embodiments, a cleavable moiety comprises a cleavable bond. In certain embodiments, a cleavable moiety is a group of atoms. In certain embodiments, a cleavable moiety is selectively cleaved inside a cell or sub-cellular compartment, such as a lysosome. In certain embodiments, a cleavable moiety is selectively cleaved by endogenous enzymes, such as nucleases. In certain embodiments, a cleavable moiety comprises a group of atoms having one, two, three, four, or more than four cleavable bonds. [0207] In certain embodiments, conjugate groups comprise a cleavable moiety. In certain such embodiments, the cleavable moiety covalently attaches the oligomeric compound to the conjugate linker. In certain such embodiments, the cleavable moiety covalently attaches the oligomeric compound to the cell-targeting moiety. [0208] In certain embodiments, a cleavable bond is selected from among an amide, a polyamide, an ester, an ether, one or both esters of a phosphodiester, a phosphate ester, a carbamate, a di-sulfide, or a peptide. In certain embodiments, a cleavable bond is one of the esters of a phosphodiester. In certain embodiments, a cleavable bond is one or both esters of a phosphodiester. In certain embodiments, the cleavable moiety is a phosphodiester linkage between an oligomeric compound and the remainder of the conjugate group. In certain embodiments, the cleavable moiety comprises a phosphodiester linkage that is located between an oligomeric compound and the remainder of the conjugate group. In certain embodiments, the cleavable moiety comprises a phosphate or phosphodiester. In certain embodiments, the cleavable moiety is attached to the conjugate linker by either a phosphodiester or a phosphorothioate linkage. In certain embodiments, the cleavable moiety is attached to the conjugate linker by a phosphodiester linkage. In certain embodiments, the conjugate group does not include a cleavable moiety. [0209] In certain embodiments, the cleavable moiety is a cleavable nucleoside or a modified nucleoside. In certain embodiments, the nucleoside or modified nucleoside comprises an optionally protected heterocyclic base selected from a purine, substituted purine, pyrimidine or substituted pyrimidine. In certain embodiments, the cleavable moiety is a nucleoside selected from uracil, thymine, cytosine, 4-N-benzoylcytosine, 5-methylcytosine, 4-N-benzoyl-5-methylcytosine, adenine, 6-N-benzoyladenine, guanine and 2-N- isobutyrylguanine. [0210] In certain embodiments, the cleavable moiety is 2′-deoxy nucleoside that is attached to either the 3′ or 5′-terminal nucleoside of an oligomeric compound by a phosphodiester linkage and covalently attached to the remainder of the conjugate group by a phosphodiester or phosphorothioate linkage. In certain embodiments, the cleavable moiety is 2′-deoxy adenosine that is attached to either the 3′ or 5′-terminal nucleoside of an oligomeric compound by a phosphodiester linkage and covalently attached to the remainder of the conjugate group by a phosphodiester or phosphorothioate linkage. In certain embodiments, the cleavable moiety is 2′-deoxy adenosine that is attached to the 3′-oxygen atom of the 3′- hydroxyl group of the 3′-terminal nucleoside or modified nucleoside by a phosphodiester linkage. In certain embodiments, the cleavable moiety is 2′-deoxy adenosine that is attached to the 5′-oxygen atom of the 5′-hydroxyl group of the 5′-terminal nucleoside or modified nucleoside by a phosphodiester linkage. In certain embodiments, the cleavable moiety is attached to a 2′-position of a nucleoside or modified nucleoside of an oligomeric compound. [0211] As used herein, “conjugate linker” in the context of a conjugate group means a portion of a conjugate group comprising any atom or group of atoms that covalently link the cell-targeting moiety to the oligomeric compound either directly or through the cleavable moiety. In certain embodiments, the conjugate linker comprises groups selected from alkyl, amino, oxo, amide, disulfide, polyethylene glycol, ether, thioether (—S—) and hydroxylamino (—O—N(H)—). In certain embodiments, the conjugate linker comprises groups selected from alkyl, amino, oxo, amide and ether groups. In certain embodiments, the conjugate linker comprises groups selected from alkyl and amide groups. In certain embodiments, the conjugate linker comprises groups selected from alkyl and ether groups. In certain embodiments, the conjugate linker comprises at least one phosphorus linking group. In certain embodiments, the conjugate linker comprises at least one phosphodiester group. In certain embodiments, the conjugate linker includes at least one neutral linking group. [0212] In certain embodiments, the conjugate linker is covalently attached to the oligomeric compound. In certain embodiments, the conjugate linker is covalently attached to the oligomeric compound and the branching group. In certain embodiments, the conjugate linker is covalently attached to the oligomeric compound and a tethered ligand. In certain embodiments, the conjugate linker is covalently attached to the cleavable moiety. In certain embodiments, the conjugate linker is covalently attached to the cleavable moiety and the branching group. In certain embodiments, the conjugate linker is covalently attached to the cleavable moiety and a tethered ligand. In certain embodiments, the conjugate linker includes one or more cleavable bonds. In certain embodiments, the conjugate group does not include a conjugate linker. [0213] As used herein, “branching group” means a group of atoms having at least 3 positions that are capable of forming covalent linkages to two or more tether-ligands and the remainder of the conjugate group. In general, a branching group provides a plurality of reactive sites for connecting tethered ligands to the oligomeric compound through the conjugate linker and/or the cleavable moiety. In certain embodiments, the branching group comprises groups selected from alkyl, amino, oxo, amide, disulfide, polyethylene glycol, ether, thioether and hydroxylamino groups. In certain embodiments, the branching group comprises a branched aliphatic group comprising groups selected from alkyl, amino, oxo, amide, disulfide, polyethylene glycol, ether, thioether and hydroxylamino groups. In certain such embodiments, the branched aliphatic group comprises groups selected from alkyl, amino, oxo, amide and ether groups. In certain such embodiments, the branched aliphatic group comprises groups selected from alkyl, amino and ether groups. In certain such embodiments, the branched aliphatic group comprises groups selected from alkyl and ether groups. In certain embodiments, the branching group comprises a mono or polycyclic ring system. [0214] In certain embodiments, the branching group is covalently attached to the conjugate linker. In certain embodiments, the branching group is covalently attached to the cleavable moiety. In certain embodiments, the branching group is covalently attached to the conjugate linker and each of the tethered ligands. In certain embodiments, the branching group comprises one or more cleavable bond. In certain embodiments, the conjugate group does not include a branching group. [0215] In certain embodiments, conjugate groups as provided herein include a cell- targeting moiety that has at least one tethered ligand. In certain embodiments, the cell- targeting moiety comprises two tethered ligands covalently attached to a branching group. In certain embodiments, the cell-targeting moiety comprises three tethered ligands covalently attached to a branching group. [0216] As used herein, “tether” means a group of atoms that connect a ligand to the remainder of the conjugate group. In certain embodiments, each tether is a linear aliphatic group comprising one or more groups selected from alkyl, substituted alkyl, ether, thioether, disulfide, amino, oxo, amide, phosphodiester and polyethylene glycol groups in any combination. In certain embodiments, each tether is a linear aliphatic group comprising one or more groups selected from alkyl, ether, thioether, disulfide, amino, oxo, amide and polyethylene glycol groups in any combination. In certain embodiments, each tether is a linear aliphatic group comprising one or more groups selected from alkyl, substituted alkyl, phosphodiester, ether and amino, oxo, amide groups in any combination. In certain embodiments, each tether is a linear aliphatic group comprising one or more groups selected from alkyl, ether and amino, oxo, amide groups in any combination. In certain embodiments, each tether is a linear aliphatic group comprising one or more groups selected from alkyl, amino and oxo groups in any combination. In certain embodiments, each tether is a linear aliphatic group comprising one or more groups selected from alkyl and oxo groups in any combination. In certain embodiments, each tether is a linear aliphatic group comprising one or more groups selected from alkyl and phosphodiester in any combination. In certain embodiments, each tether comprises at least one phosphorus linking group or neutral linking group. [0217] In certain embodiments, tethers include one or more cleavable bond. In certain embodiments, each tethered ligand is attached to a branching group. In certain embodiments, each tethered ligand is attached to a branching group through an amide group. In certain embodiments, each tethered ligand is attached to a branching group through an ether group. In certain embodiments, each tethered ligand is attached to a branching group through a phosphorus linking group or neutral linking group. In certain embodiments, each tethered ligand is attached to a branching group through a phosphodiester group. In certain embodiments, each tether is attached to a ligand through either an amide or an ether group. In certain embodiments, each tether is attached to a ligand through an ether group. [0218] In certain embodiments, each tether comprises from about 8 to about 20 atoms in chain length between the ligand and the branching group. In certain embodiments, each tether comprises from about 10 to about 18 atoms in chain length between the ligand and the branching group. In certain embodiments, each tether comprises about 13 atoms in chain length. [0219] In certain embodiments, the present disclosure provides ligands wherein each ligand is covalently attached to the remainder of the conjugate group through a tether. In certain embodiments, each ligand is selected to have an affinity for at least one type of receptor on a target cell. In certain embodiments, ligands are selected that have an affinity for at least one type of receptor on the surface of a mammalian liver cell. In certain embodiments, ligands are selected that have an affinity for the hepatic asialoglycoprotein receptor (ASGP-R). In certain embodiments, each ligand is a carbohydrate. In certain embodiments, each ligand is, independently selected from galactose, N-acetyl galactoseamine, mannose, glucose, glucosamone and fucose. In certain embodiments, each ligand is N-acetyl galactoseamine (GalNAc). In certain embodiments, the targeting moiety comprises 1 to 3 ligands. In certain embodiments, the targeting moiety comprises 3 ligands. In certain embodiments, the targeting moiety comprises 2 ligands. In certain embodiments, the targeting moiety comprises 1 ligand. In certain embodiments, the targeting moiety comprises 3 N-acetyl galactoseamine ligands. In certain embodiments, the targeting moiety comprises 2 N-acetyl galactoseamine ligands. In certain embodiments, the targeting moiety comprises 1 N-acetyl galactoseamine ligand. [0220] In certain embodiments, each ligand is a carbohydrate, carbohydrate derivative, modified carbohydrate, multivalent carbohydrate cluster, polysaccharide, modified polysaccharide, or polysaccharide derivative. In certain embodiments, each ligand is an amino sugar or a thio sugar. For example, amino sugars may be selected from any number of compounds known in the art, for example glucosamine, sialic acid, α-D- galactosamine, N-Acetylgalactosamine, 2-acetamido-2-deoxy-D-galactopyranose (GalNAc), 2-Amino-3-O—[®-1-carboxyethyl]-2-deoxy-β-D-glucopyranose (β-muramic acid), 2-Deoxy- 2-methylamino-L-glucopyranose, 4,6-Dideoxy-4-formamido-2,3-di-O-methyl-D- mannopyranose, 2-Deoxy-2-sulfoamino-D-glucopyranose and N-sulfo-D-glucosamine, and N-Glycoloyl-α-neuraminic acid. For example, thio sugars may be selected from the group consisting of 5-Thio-β-D-glucopyranose, Methyl 2,3,4-tri-O-acetyl-1-thio-6-O-trityl-α-D- glucopyranoside, 4-Thio-β-D-galactopyranose, and ethyl 3,4,6,7-tetra-O-acetyl-2-deoxy-1,5- dithio-α-D-gluco-heptopyranoside. [0221] In certain embodiments, conjugate groups as provided herein comprise a carbohydrate cluster. As used herein, “carbohydrate cluster” means a portion of a conjugate group wherein two or more carbohydrate residues are attached to a branching group through tether groups. (see, e.g., Maier et al., “Synthesis of Antisense Oligonucleotides Conjugated to a Multivalent Carbohydrate Cluster for Cellular Targeting,” Bioconjugate Chemistry, 2003, (14): 18-29, which is incorporated herein by reference in its entirety, or Rensen et al., “Design and Synthesis of Novel N-Acetylgalactosamine-Terminated Glycolipids for Targeting of Lipoproteins to the Hepatic Asiaglycoprotein Receptor,” J. Med. Chem.2004, (47): 5798-5808, for examples of carbohydrate conjugate clusters). [0222] As used herein, “modified carbohydrate” means any carbohydrate having one or more chemical modifications relative to naturally occurring carbohydrates. [0223] As used herein, “carbohydrate derivative” means any compound which may be synthesized using a carbohydrate as a starting material or intermediate. [0224] As used herein, “carbohydrate” means a naturally occurring carbohydrate, a modified carbohydrate, or a carbohydrate derivative. [0225] In certain embodiments, conjugate groups are provided wherein the cell- targeting moiety has the formula: [0226] In certain embodiments, conjugate groups are provided wherein the cell- targeting moiety has the formula:
[0227] In certain embodiments, conjugate groups are provided wherein the cell- targeting moiety has the formula: [0228] In certain embodiments, conjugate groups have the formula:
[0229] Representative United States patents, United States patent application publications, and international patent application publications that teach the preparation of certain of the above noted conjugate groups, conjugated oligomeric compounds such as ASOs comprising a conjugate group, tethers, conjugate linkers, branching groups, ligands, cleavable moieties as well as other modifications include without limitation, U.S. Pat. Nos. 5,994,517, 6,300,319, 6,660,720, 6,906,182, 7,262,177, 7,491,805, 8,106,022, 7,723,509, US 2006/0148740, US 2011/0123520, WO 2013/033230 and WO 2012/037254, each of which is incorporated by reference herein in its entirety. [0230] Representative publications that teach the preparation of certain of the above noted conjugate groups, conjugated oligomeric compounds such as ASOs comprising a conjugate group, tethers, conjugate linkers, branching groups, ligands, cleavable moieties as well as other modifications include without limitation, BIESSEN et al., “The Cholesterol Derivative of a Triantennary Galactoside with High Affinity for the Hepatic Asialoglycoprotein Receptor: a Potent Cholesterol Lowering Agent” J. Med. Chem. (1995) 38:1846-1852, BIESSEN et al., “Synthesis of Cluster Galactosides with High Affinity for the Hepatic Asialoglycoprotein Receptor” J. Med. Chem. (1995) 38:1538-1546, LEE et al., “New and more efficient multivalent 50daman-ligands for asialoglycoprotein receptor of mammalian hepatocytes” Bioorganic & Medicinal Chemistry (2011) 19:2494-2500, RENSEN et al., “Determination of the Upper Size Limit for Uptake and Processing of Ligands by the Asialoglycoprotein Receptor on Hepatocytes in Vitro and in Vivo” J. Biol. Chem. (2001) 276(40):37577-37584, RENSEN et al., “Design and Synthesis of Novel N- Acetylgalactosamine-Terminated Glycolipids for Targeting of Lipoproteins to the Hepatic Asialoglycoprotein Receptor” J. Med. Chem. (2004) 47:5798-5808, SLIEDREGT et al., “Design and Synthesis of Novel Amphiphilic Dendritic Galactosides for Selective Targeting of Liposomes to the Hepatic Asialoglycoprotein Receptor” J. Med. Chem. (1999) 42:609- 618, and Valentijn et al., “Solid-phase synthesis of lysine-based cluster galactosides with high affinity for the Asialoglycoprotein Receptor” Tetrahedron, 1997, 53(2), 759-770, each of which is incorporated by reference herein in its entirety. [0231] In certain embodiments, conjugate groups include without limitation, intercalators, reporter molecules, polyamines, polyamides, polyethylene glycols, thioethers, polyethers, cholesterols, thiocholesterols, cholic acid moieties, folate, lipids, phospholipids, biotin, phenazine, phenanthridine, anthraquinone, adamantine, acridine, fluoresceins, rhodamines, coumarins and dyes. Certain conjugate groups have been described previously, for example: cholesterol moiety (Letsinger et al., Proc. Natl. Acad. Sci. USA, 1989, 86, 6553- 6556), cholic acid (Manoharan et al., Bioorg. Med. Chem. Let., 1994, 4, 1053-1060), a thioether, e.g., hexyl-S-tritylthiol (Manoharan et al., Ann. N.Y. Acad. Sci., 1992, 660, 306- 309; Manoharan et al., Bioorg. Med. Chem. Let., 1993, 3, 2765-2770), a thiocholesterol (Oberhauser et al., Nucl. Acids Res., 1992, 20, 533-538), an aliphatic chain, e.g., do-decan- diol or undecyl residues (Saison-Behmoaras et al., EMBO J., 1991, 10, 1111-1118; Kabanov et al., FEBS Lett., 1990, 259, 327-330; Svinarchuk et al., Biochimie, 1993, 75, 49-54), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethyl-ammonium 1,2-di-O-hexadecyl-rac- glycero-3-H-phosphonate (Manoharan et al., Tetrahedron Lett., 1995, 36, 3651-3654; Shea et al., Nucl. Acids Res., 1990, 18, 3777-3783), a polyamine or a polyethylene glycol chain (Manoharan et al., Nucleosides & Nucleotides, 1995, 14, 969-973), or 4amantine acetic acid (Manoharan et al., Tetrahedron Lett., 1995, 36, 3651-3654), a palmityl moiety (Mishra et al., Biochim. Biophys. Acta, 1995, 1264, 229-237), or an octadecylamine or hexylamino- carbonyl-oxycholesterol moiety (Crooke et al., J. Pharmacol. Exp. Ther., 1996, 277, 923- 937). [0232] In certain embodiments, a conjugate group comprises an active drug substance, for example, aspirin, warfarin, phenylbutazone, ibuprofen, suprofen, fen-bufen, ketoprofen, (S)-(+)-pranoprofen, carprofen, dansylsarcosine, 2,3,5-triiodobenzoic acid, flufenamic acid, folinic acid, a benzothiadiazide, chlorothiazide, a diazepine, indo-methicin, a barbiturate, a cephalosporin, a sulfa drug, an antidiabetic, an antibacterial or an antibiotic. [0233] Some nonlimiting examples of conjugate linkers include pyrrolidine, 8-amino- 3,6-dioxaoctanoic acid (ADO), succinimidyl 4-(N-maleimidomethyl) cyclohexane-1- carboxylate (SMCC) and 6-aminohexanoic acid (AHEX or AHA). Other conjugate linkers include, but are not limited to, substituted C1-C10 alkyl, substituted or unsubstituted C2-C10 alkenyl or substituted or unsubstituted C2-C10 alkynyl, wherein a nonlimiting list of preferred substituent groups includes hydroxyl, amino, alkoxy, carboxy, benzyl, phenyl, nitro, thiol, thioalkoxy, halogen, alkyl, aryl, alkenyl and alkynyl. [0234] Conjugate groups may be attached to either or both ends of an oligonucleotide (terminal conjugate groups) and/or at any internal position. [0235] In certain embodiments, conjugate groups are at the 3′-end of an oligonucleotide of an oligomeric compound. In certain embodiments, conjugate groups are near the 3′-end. In certain embodiments, conjugates are attached at the 3′ end of an oligomeric compound, but before one or more terminal group nucleosides. In certain embodiments, conjugate groups are placed within a terminal group. III. Pharmaceutical Compositions [0236] Another aspect of the present application relates to a pharmaceutical composition comprising one or more ASOs of the present application and a pharmaceutically acceptable carrier. [0237] In some embodiments, the pharmaceutical composition comprises one or more anti-fibrosis gene-enhancing ASOs. [0238] In some embodiments, the pharmaceutical composition comprises one or more pro-fibrosis gene-inhibiting ASOs. In some embodiments, the one or more pro-fibrosis gene- inhibiting ASOs are selected from the group consisting of SEQ ID NOS:17 and 41. [0239] In some embodiments, the pharmaceutical composition comprises (1) anti- fibrosis gene-enhancing ASOs and (2) one or more pro-fibrosis gene-inhibiting ASOs. [0240] In some embodiments, the one or more anti-fibrosis gene-enhancing ASOs are selected from the group consisting of SEQ ID NOS:8, 9, 19, 15, 21, 45 and 46. [0241] In some embodiments, the one or more pro-fibrosis gene-inhibiting ASOs are selected from the group consisting of SEQ ID NOS:17 and 41. [0242] In some embodiments, the pharmaceutical composition comprises one or more carriers suitable for delivering the therapeutic agents to heart tissues. Exemplary carriers for delivery include nanoparticles, lipids, liposomes, micelles, polymers, polymeric micelles, emulsions, polyelectrolyte complexes, hydrogels, microcapsules, viruses, virus-like particle (VLPs), peptides, antibodies, aptamers, small molecule chemicals, exosomes, combinations thereof, and pegylated derivatives thereof. In a particular embodiment, the pharmaceutical composition comprises a nanoparticle formulation comprising an ASO in accordance with the present application. [0243] In certain particular embodiments, the above-described carriers, including nanoparticles, may be linked to the heart tissue-specific targeting peptides or antibodies to facilitate carrier-mediated delivery of the active agents described herein to heart tissues. For example, in certain embodiments, pharmaceutical compositions include nanoparticles or liposomes covalently or non-covalently coated with a heart tissue-specific targeting peptide or antibody. [0244] Exemplary nanoparticles include paramagnetic nanoparticles, superparamagnetic nanoparticles, metal nanoparticles, polymeric nanoparticles, nanoworms, nanoemulsions, nanogels, fullerene-like materials, inorganic nanotubes, dendrimers (such as with covalently attached metal chelates), nanocapsules, nanospheres, nanofibers, nanohoms, nano-onions, nanorods, nanoropes and quantum dots. A nanoparticle can produce a detectable signal, for example, through absorption and/or emission of photons (including radio frequency and visible photons) and plasmon resonance. Nanoparticles can be biodegradable or non-biodegradable. [0245] In certain embodiments, the nanoparticle is a metal nanoparticle, a metal oxide nanoparticle, or a semiconductor nanocrystal. The metal of the metal nanoparticle or the metal oxide nanoparticle can include titanium, zirconium, hafnium, vanadium, niobium, tantalum, chromium, molybdenum, tungsten, manganese, technetium, rhenium, iron, ruthenium, osmium, cobalt, rhodium, iridium, nickel, palladium, platinum, copper, silver, gold, zinc, cadmium, scandium, yttrium, lanthanum, a lanthanide series or actinide series element (e.g., cerium, praseodymium, neodymium, promethium, samarium, europium, gadolinium, terbium, dysprosium, holmium, erbium, thulium, ytterbium, lutetium, thorium, protactinium, and uranium), boron, aluminum, gallium, indium, thallium, silicon, germanium, tin, lead, antimony, bismuth, polonium, magnesium, calcium, strontium, and barium. In certain embodiments, the metal can be iron, ruthenium, cobalt, rhodium, nickel, palladium, platinum, silver, gold, cerium or samarium. The metal oxide can be an oxide of any of these materials or combination of materials. For example, the metal can be gold, or the metal oxide can be an iron oxide, a cobalt oxide, a zinc oxide, a cerium oxide, or a titanium oxide. Preparation of metal and metal oxide nanoparticles is described, for example, in U.S. Pat. Nos.5,897,945 and 6,759,199. [0246] In other embodiments, a polymeric nanoparticle is made from a synthetic biodegradable polymer, a natural biodegradable polymer or a combination thereof. Synthetic biodegradable polymers can include, polyesters, such as poly(lactic-co-glycolic acid)(PLGA) and polycaprolactone; polyorthoesters, polyanhydrides, polydioxanones, poly-alkyl-cyano- acrylates (PAC), polyoxalates, polyiminocarbonates, polyurethanes, polyphosphazenes, or a combination thereof. Natural biodegradable polymers can include starch, hyaluronic acid, heparin, gelatin, albumin, chitosan, dextran, or a combination thereof. [0247] In some embodiments, the pharmaceutical composition comprises a delivery carrier, such as a nanoparticle or liposome encapsulating a pharmaceutically effective amount of the antisense oligonucleotide. In some embodiments, the pharmaceutically effective amount of an ASO is from about 0.001 µg/mL to about 10 µg/mL (w/v) of the pharmaceutically acceptable carrier. In some embodiments, the pharmaceutically effective amount of ASO is from about 0.1 µg/mL to about 1 µg/mL (w/v) of the pharmaceutically acceptable carrier. [0248] In some embodiments, the pharmaceutical composition comprises an ASO of the present application and a lipid moiety. Lipid moieties have been used in nucleic acid therapies in a variety of methods. In certain such methods, the nucleic acid is introduced into preformed liposomes or lipoplexes made of mixtures of cationic lipids and neutral lipids. In certain methods, DNA complexes with mono- or poly-cationic lipids are formed without the presence of a neutral lipid. In certain embodiments, the lipid moiety is selected to increase distribution of a pharmaceutical agent to heart tissue. In certain embodiments, the lipid moiety is selected to increase distribution of the pharmaceutical agent to heart muscle. [0249] In certain embodiments, pharmaceutical compositions provided herein include one or more ASOs and one or more excipients. Exemplary excipients include water, salt solutions, alcohol, polyethylene glycols, gelatin, lactose, amylase, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose, polyvinylpyrrolidone and combinations thereof. In certain embodiments, the pharmaceutical compositions including one or more hydrophobic compounds, including organic solvents, such as dimethylsulfoxide. [0250] In certain embodiments, the pharmaceutical composition provided herein comprises a co-solvent system. Co-solvent systems may include, for example, benzyl alcohol, a nonpolar surfactant, a water-miscible organic polymer, and an aqueous phase. In certain embodiments, such co-solvent systems are used for hydrophobic compounds. A non-limiting example of such a co-solvent system is the VPD co-solvent system, which is a solution of absolute ethanol comprising 3% w/v benzyl alcohol, 8% w/v of the nonpolar surfactant Polysorbate 80™ and 65% w/v polyethylene glycol 300. The proportions of such co-solvent systems may be varied considerably without significantly altering their solubility and toxicity characteristics. Furthermore, the identity of co-solvent components may be varied. For example, other surfactants may be used instead of Polysorbate 80™; the fraction size of polyethylene glycol may be varied; other biocompatible polymers may replace polyethylene glycol, e.g., polyvinyl pyrrolidone; and other sugars or polysaccharides may substitute for dextrose. [0251] In some embodiments, the pharmaceutical composition comprises a sterile saline solution and one or more ASOs. In certain embodiments, the pharmaceutical composition consists of a sterile saline solution and one or more ASOs. In certain embodiments, the sterile saline is pharmaceutical grade saline. In certain embodiments, the pharmaceutical composition comprises one or more ASOs and sterile water. In certain embodiments, a pharmaceutical composition consists of one or more ASOs and sterile water. In certain embodiments, the sterile saline is pharmaceutical grade water. In certain embodiments, the pharmaceutical composition comprises one or more ASOs and phosphate- buffered saline (PBS). In certain embodiments, a pharmaceutical composition consists of one or more ASOs and sterile phosphate-buffered saline (PBS). In certain embodiments, the sterile saline is pharmaceutical grade PBS. [0252] In certain embodiments, ASOs are admixed with pharmaceutically acceptable active and/or inert substances for the preparation of pharmaceutical compositions or formulations. Compositions and methods for the formulation of pharmaceutical compositions can depend on a number of criteria, including, but not limited to, route of administration, extent of disease, and/or dose to be administered. [0253] Pharmaceutical compositions comprising ASOs may include any pharmaceutically acceptable salts, esters, or salts of such esters. In certain embodiments, pharmaceutical compositions comprising ASOs comprise one or more oligonucleotides, which, upon administration to an animal, such as a human, is capable of providing (directly or indirectly) the biologically active metabolite or residue thereof. Accordingly, for example, the disclosure is also drawn to pharmaceutically acceptable salts of ASOs, prodrugs, pharmaceutically acceptable salts of such prodrugs, and other bioequivalents. Suitable pharmaceutically acceptable salts include, but are not limited to, sodium and potassium salts. [0254] A prodrug can include the incorporation of additional nucleosides at one or both ends of an oligomeric compound which are cleaved by endogenous nucleases within the body, to form the active compound. [0255] The pharmaceutical composition of the present application is formulated in accordance with the particular route of administration. Routes of administration for the therapeutic agents of the present application include oral and parenteral administration, i.e., injection, infusion, or implantation or by some other route other than the alimentary canal. Specific modes of administration include injections, such as intravenous, intramyocardial, intramuscular, intrapleural, intravascular, intrapericardial, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intra-articular, subcapsular, subarachnoid, intraspinal and intrastemal injection and infusion. [0256] In certain preferred embodiments, the pharmaceutical composition is formulated for administration by intravenous or intramyocardial injection. In certain embodiments, the pharmaceutical composition is formulated in aqueous solution, such as water or physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiological saline buffer. In certain embodiments, other ingredients are included (e.g., ingredients that aid in solubility or that serve as preservatives). In certain embodiments, injectable suspensions are prepared using appropriate liquid carriers, suspending agents and the like. Certain pharmaceutical compositions for injection are presented in unit dosage form, e.g., in ampoules or in multi-dose containers. Some pharmaceutical compositions for injection are suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Certain solvents suitable for use in pharmaceutical compositions for injection include, but are not limited to, lipophilic solvents and fatty oils, such as sesame oil, synthetic fatty acid esters, such as ethyl oleate or triglycerides, and liposomes. Aqueous injection suspensions may contain. IV. Methods for Treating Cardiac Fibrosis [0257] Another aspect of the present application relates to a method for treating cardiac fibrosis in a subject. The method includes the step of administering to a subject in need of such treatment an effective amount of a pharmaceutical composition comprising an ASO of the present application. [0258] In some embodiment, the method comprises the administration of a pharmaceutical composition comprising one or more anti-fibrosis gene-enhancing ASOs. [0259] In some embodiment, the method comprises the administration of a pharmaceutical composition comprising one or more pro-fibrosis gene inhibiting ASOs. [0260] In some embodiments, the method comprises the administration of a pharmaceutical composition comprises (1) anti-fibrosis gene enhancing ASOs and (2) one or more pro-fibrosis gene-inhibiting ASOs. [0261] In some embodiments, the one or more anti-fibrosis gene-enhancing are selected from the group consisting of SEQ ID NOS:8, 9, 19, 15, 21, 45 and 46. [0262] In some embodiments, the one or more pro-fibrosis gene-inhibiting ASOs are selected from the group consisting of SEQ ID NOS:17 and 41. [0263] In another embodiment, the method comprises administration of a pharmaceutical composition containing an ASO formulated in a nanoparticle formulation. [0264] In one embodiment, the method comprises administering the pharmaceutical composition to the subject intravenously or intramyocardially. [0265] In some embodiments, the ASO dosage may be expressed as the amount of the compound that results in amelioration of symptoms or a prolongation of survival in a patient. Toxicity and therapeutic efficacy of the ASO can be determined by standard pharmaceutical procedures in cell cultures or experimental animals (e.g., for determining the LD50--the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index, which can be expressed as the ratio between LD50 and ED50. Compounds exhibiting high therapeutic indices are preferred. The data obtained from cell culture assays and animal studies can be used in formulating a range of dosages or amounts for use in mammals (e.g., humans). The dosage or amount of an ASO preferably lies within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage or amount may vary within this range depending upon the dosage form employed and the route of administration utilized. The exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition. Dosage amount and interval may be adjusted individually to provide plasma levels of the active moiety which are sufficient to maintain the desired effects. [0266] In certain embodiments, the ASO can be administered to a mammal having, suspected of having, or at risk of cardiac fibrosis and/or related pathologies at an amount sufficient to reduce target protein expression or activity. In accordance with certain embodiments, the ASO can be administered in a dose suitable for reducing target protein expression by at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or any range thereof. [0267] Dosages for a particular patient can be determined by one of ordinary skill in the art using conventional considerations, (e.g., by means of an appropriate, conventional pharmacological protocol). A physician may, for example, prescribe a relatively low dose at first, subsequently increasing the dose until an appropriate response is obtained. The dose administered to a patient is sufficient to effect a beneficial therapeutic response in the patient over time, or, e.g., to reduce symptoms, or other appropriate activity, depending on the application. The dose can be determined by the efficacy of the particular formulation, and the activity, stability or serum half-life of the ASO employed and the condition of the patient, as well as the body weight or surface area of the patient to be treated. The size of the dose can also be determined by the existence, nature, and extent of any adverse side-effects that accompany the administration of a particular composition in a particular patient. [0268] Optimal precision in achieving effective ASO concentrations within a range yielding maximum efficacy with minimal toxicity may require a regimen based on the kinetics of the pharmaceutical composition's availability to the targeted heart tissues. Distribution, equilibrium, and elimination of a pharmaceutical composition may be considered when determining the optimal concentration for a treatment regimen. Generally, the pharmaceutical compositions of the present invention may be administered in a manner that maximizes efficacy and minimizes toxicity. [0269] Moreover, the dosage administration of the compositions of the present invention may be optimized using a pharmacokinetic/pharmacodynamic modeling system. For example, one or more dosage regimens may be chosen and a pharmacokinetic/pharmacodynamic model may be used to determine the pharmacokinetic/pharmacodynamic profile of one or more dosage regimens. Next, one of the dosage regimens for administration may be selected which achieves the desired pharmacokinetic/pharmacodynamic response based on the particular pharmacokinetic/pharmacodynamic profile. See e.g., US 6,747,002, which is entirely expressly incorporated herein by reference. [0270] More specifically, the pharmaceutical compositions may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three, or four times daily. In the case of oral administration, the daily dosage of the compositions may be varied over a wide range from about 0.1 ng to about 1,000 mg per patient, per day. The range may more particularly be from about 0.001 ng/kg to 10 mg/kg of body weight per day, about 0.1-100 µg, about 1.0-50 µg or about 1.0-20 mg per day for adults (at about 60 kg). [0271] The daily dosage of the pharmaceutical compositions may be varied over a wide range from about 0.1 ng to about 1000 mg per adult human per day. For oral administration, the compositions may be provided in the form of tablets containing from about 0.1 ng to about 1000 mg of the composition or 0.1, 0.2, 0.5, 1.0, 2.0, 5.0, 10.0, 15.0, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 800, 900, or 1000 milligrams of the composition for the symptomatic adjustment of the dosage to the patient to be treated. An effective amount of the pharmaceutical composition is ordinarily supplied at a dosage level of from about 0.1 ng/kg to about 20 mg/kg of body weight per day. In one embodiment, the range is from about 0.2 ng/kg to about 10 mg/kg of body weight per day. In another embodiment, the range is from about 0.5 ng/kg to about 10 mg/kg of body weight per day. The pharmaceutical compositions may be administered on a regimen of about 1 to about 10 times per day. [0272] In the case of injections, it is usually convenient to give by an intravenous route in an amount of about 0.01 µg-30 mg, about 0.01 µg-20 mg or about 0.01-10 mg per day to adults (at about 60 kg). In the case of other animals, the dose calculated for 60 kg may be administered as well. [0273] Doses of a pharmaceutical composition of the present invention can optionally include 0.0001 µg to 1,000 mg/kg/administration, or 0.001 µg to 100.0 mg/kg/administration, from 0.01 µg to 10 mg/kg/administration, from 0.1 µg to 10 mg/kg/administration, including, but not limited to, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 and/or 100-500 mg/kg/administration or any range, value or fraction thereof, or to achieve a serum concentration of 0.1, 0.5, 0.9, 1.0, 1.1, 1.2, 1.5, 1.9, 2.0, 2.5, 2.9, 3.0, 3.5, 3.9, 4.0, 4.5, 4.9, 5.0, 5.5, 5.9, 6.0, 6.5, 6.9, 7.0, 7.5, 7.9, 8.0, 8.5, 8.9, 9.0, 9.5, 9.9, 10, 10.5, 10.9, 11, 11.5, 11.9, 20, 12.5, 12.9, 13.0, 13.5, 13.9, 14.0, 14.5, 4.9, 5.0, 5.5, 5.9, 6.0, 6.5, 6.9, 7.0, 7.5, 7.9, 8.0, 8.5, 8.9, 9.0, 9.5, 9.9, 10, 10.5, 10.9, 11, 11.5, 11.9, 12, 12.5, 12.9, 13.0, 13.5, 13.9, 14, 14.5, 15, 15.5, 15.9, 16, 16.5, 16.9, 17, 17.5, 17.9, 18, 18.5, 18.9, 19, 19.5, 19.9, 20, 20.5, 20.9, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 96, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, and/or 5000 m/ml serum concentration per single or multiple administration or any range, value or fraction thereof. [0274] As a non-limiting example, treatment of humans or animals can be provided as a onetime or periodic dosage of a composition of the present invention 0.1 ng to 100 mg/kg such as 0.0001, 0.001, 0.01, 0.10.5, 0.9, 1.0, 1.1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 40, 45, 50, 60, 70, 80, 90 or 100 mg/kg, per day, on at least one of day 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40, or alternatively or additionally, at least one of week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, or 52, or alternatively or additionally, at least one of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 years, or any combination thereof, using single, infusion or repeated doses. [0275] Specifically, the pharmaceutical compositions may be administered at least once a week over the course of several weeks. In one embodiment, the pharmaceutical compositions are administered at least once a week over several weeks to several months. In another embodiment, the pharmaceutical compositions are administered once a week over four to eight weeks. In yet another embodiment, the pharmaceutical compositions are administered once a week over four weeks. [0276] More specifically, the pharmaceutical compositions may be administered at least once a day for about 2 days, at least once a day for about 3 days, at least once a day for about 4 days, at least once a day for about 5 days, at least once a day for about 6 days, at least once a day for about 7 days, at least once a day for about 8 days, at least once a day for about 9 days, at least once a day for about 10 days, at least once a day for about 11 days, at least once a day for about 12 days, at least once a day for about 13 days, at least once a day for about 14 days, at least once a day for about 15 days, at least once a day for about 16 days, at least once a day for about 17 days, at least once a day for about 18 days, at least once a day for about 19 days, at least once a day for about 20 days, at least once a day for about 21 days, at least once a day for about 22 days, at least once a day for about 23 days, at least once a day for about 24 days, at least once a day for about 25 days, at least once a day for about 26 days, at least once a day for about 27 days, at least once a day for about 28 days, at least once a day for about 29 days, at least once a day for about 30 days, or at least once a day for about 31 days. [0277] Alternatively, the pharmaceutical compositions may be administered about once every day, about once every 2 days, about once every 3 days, about once every 4 days, about once every 5 days, about once every 6 days, about once every 7 days, about once every 8 days, about once every 9 days, about once every 10 days, about once every 11 days, about once every 12 days, about once every 13 days, about once every 14 days, about once every 15 days, about once every 16 days, about once every 17 days, about once every 18 days, about once every 19 days, about once every 20 days, about once every 21 days, about once every 22 days, about once every 23 days, about once every 24 days, about once every 25 days, about once every 26 days, about once every 27 days, about once every 28 days, about once every 29 days, about once every 30 days, or about once every 31 days. The pharmaceutical compositions of the present invention may alternatively be administered about once every week, about once every 2 weeks, about once every 3 weeks, about once every 4 weeks, about once every 5 weeks, about once every 6 weeks, about once every 7 weeks, about once every 8 weeks, about once every 9 weeks, about once every 10 weeks, about once every 11 weeks, about once every 12 weeks, about once every 13 weeks, about once every 14 weeks, about once every 15 weeks, about once every 16 weeks, about once every 17 weeks, about once every 18 weeks, about once every 19 weeks, about once every 20 weeks. [0278] Alternatively, the pharmaceutical compositions may be administered about once every month, about once every 2 months, about once every 3 months, about once every 4 months, about once every 5 months, about once every 6 months, about once every 7 months, about once every 8 months, about once every 9 months, about once every 10 months, about once every 11 months, or about once every 12 months. [0279] Alternatively, the pharmaceutical compositions may be administered at least once a week for about 2 weeks, at least once a week for about 3 weeks, at least once a week for about 4 weeks, at least once a week for about 5 weeks, at least once a week for about 6 weeks, at least once a week for about 7 weeks, at least once a week for about 8 weeks, at least once a week for about 9 weeks, at least once a week for about 10 weeks, at least once a week for about 11 weeks, at least once a week for about 12 weeks, at least once a week for about 13 weeks, at least once a week for about 14 weeks, at least once a week for about 15 weeks, at least once a week for about 16 weeks, at least once a week for about 17 weeks, at least once a week for about 18 weeks, at least once a week for about 19 weeks, or at least once a week for about 20 weeks. [0280] Alternatively the pharmaceutical compositions may be administered at least once a week for about 1 month, at least once a week for about 2 months, at least once a week for about 3 months, at least once a week for about 4 months, at least once a week for about 5 months, at least once a week for about 6 months, at least once a week for about 7 months, at least once a week for about 8 months, at least once a week for about 9 months, at least once a week for about 10 months, at least once a week for about 11 months, or at least once a week for about 12 months. Combination Therapy [0281] In some embodiments, the ASO of the present application can be administered in combination with one or more other therapeutic agents. The ASO of the present application and other therapeutic agents can be administered simultaneously or sequentially by the same or different routes of administration. The determination of the identity and amount of therapeutic agent(s) for use in the methods described herein can be readily made by ordinarily skilled medical practitioners using standard techniques known in the art. Generally, the ASO of the present application is administered in combination with an effective amount of another therapeutic agent that treats cardiac fibrosis and/or any heart disease or heart disease symptom associated with cardiac fibrosis. [0282] Other therapeutic agents include, but are not limited to, beta blockers, anti- hypertensives, cardiotonics, anti-thrombotics, vasodilators, hormone antagonists, inotropes, diuretics, endothelin antagonists, calcium channel blockers, phosphodiesterase inhibitors, ACE inhibitors, angiotensin type 2 antagonists and cytokine blockers/inhibitors, and HDAC inhibitors. [0283] More specifically, an ASO may be combined with another therapeutic agent including, but not limited to, an antihyperlipoproteinemic agent, an antiarteriosclerotic agent, an antithrombotic/fibrinolytic agent, a blood coagulant, an antiarrhythmic agent, an antihypertensive agent, a vasopressor, a treatment agent for congestive heart failure, an antianginal agent, an antibacterial agent or a combination thereof. [0284] In specific embodiments, the ASO of the present application is combined with an antihyperlipoproteinemic agent including aryloxyalkanoic/fibric acid derivative, a resin/bile acid sequesterant, a HMG CoA reductase inhibitor, a nicotinic acid derivative, a thyroid hormone or thyroid hormone analog, a miscellaneous agent or a combination thereof, acifran, azacosterol, benfluorex, β-benzalbutyramide, carnitine, chondroitin sulfate, clomestrone, detaxtran, dextran sulfate sodium, eritadenine, furazabol, meglutol, melinamide, mytatrienediol, ornithine, γ-oryzanol, pantethine, pentaerythritol tetraacetate, phenylbutyramide, pirozadil, probucol (lorelco), β-sitosterol, sultosilic acid-piperazine salt, tiadenol, triparanol and xenbucin. [0285] In some embodiments, the ASO of the present application is combined with an antiarteriosclerotic agent such as pyridinol carbamate. In other embodiments, the ASO is combined with an antithrombotic/fibrinolytic agent including, but not limited to anticoagulants (acenocoumarol, ancrod, anisindione, bromindione, clorindione, coumetarol, cyclocumarol, dextran sulfate sodium, dicumarol, diphenadione, ethyl biscoumacetate, ethylidene dicoumarol, fluindione, heparin, hirudin, lyapolate sodium, oxazidione, pentosan polysulfate, phenindione, phenprocoumon, phosvitin, picotamide, tioclomarol and warfarin); anticoagulant antagonists, antiplatelet agents (aspirin, a dextran, dipyridamole (persantin), heparin, sulfinpyranone (anturane) and ticlopidine (ticlid)); thrombolytic agents (tissue plaminogen activator (activase), plasmin, pro-urokinase, urokinase (abbokinase) streptokinase (streptase), anistreplase/APSAC (eminase)); thrombolytic agent antagonists or combinations thereof). [0286] In other embodiments, the ASO is combined with a blood coagulant including, but not limited to, thrombolytic agent antagonists (amiocaproic acid (amicar) and tranexamic acid (amstat); antithrombotics (anagrelide, argatroban, cilstazol, daltroban, defibrotide, enoxaparin, fraxiparine, indobufen, lamoparan, ozagrel, picotamide, plafibride, tedelparin, ticlopidine and triflusal); and anticoagulant antagonists (protamine and vitamin K1). [0287] Alternatively, the ASO may be combined with an antiarrhythmic agent including, but not limited to, Class I antiarrythmic agents (sodium channel blockers), Class II antiarrythmic agents (beta-adrenergic blockers), Class III antiarrythmic agents (repolarization prolonging drugs), Class IV antiarrhythmic agents (calcium channel blockers) and miscellaneous antiarrythmic agents. Non-limiting examples of sodium channel blockers include Class IA (disppyramide (norpace), procainamide (pronestyl) and quinidine (quinidex)); Class IB (lidocaine (xylocalne), tocamide (tonocard) and mexiletine (mexitil)); and Class IC antiarrhythmic agents, (encamide (enkaid) and fiecamide (tambocor)). [0288] Non-limiting examples of a beta blocker (also known as a β-adrenergic blocker, a β-adrenergic antagonist or a Class II antiarrhythmic agent) include acebutolol (sectral), alprenolol, amosulalol, arotinolol, atenolol, befunolol, betaxolol, bevantolol, bisoprolol, bopindolol, bucumolol, bufetolol, bufuralol, bunitrolol, bupranolol, butidrine hydrochloride, butofilolol, carazolol, carteolol, carvedilol, celiprolol, cetamolol, cloranolol, dilevalol, epanolol, esmolol (brevibloc), indenolol, labetalol, levobunolol, mepindolol, metipranolol, metoprolol, moprolol, nadolol, nadoxolol, nifenalol, nipradilol, oxprenolol, penbutolol, pindolol, practolol, pronethalol, propanolol (inderal), sotalol (betapace), sulfmalol, talinolol, tertatolol, timolol, toliprolol and xibinolol. In certain aspects, the beta blocker comprises an aryloxypropanolamine derivative. Non-limiting examples of aryloxypropanolamine derivatives include acebutolol, alprenolol, arotinolol, atenolol, betaxolol, bevantolol, bisoprolol, bopindolol, bunitrolol, butofilolol, carazolol, carteolol, carvedilol, celiprolol, cetamolol, epanolol, indenolol, mepindolol, metipranolol, metoprolol, moprolol, nadolol, nipradilol, oxprenolol, penbutolol, pindolol, propanolol, talinolol, tertatolol, timolol and toliprolol. Non-limiting examples of an agent that prolongs repolarization, also known as a Class III antiarrhythmic agent, include amiodarone (cordarone) and sotalol (betapace). [0289] Non-limiting examples of a calcium channel blocker, otherwise known as a Class IV antiarrythmic agent, include an arylalkylamine (e.g., bepridile, diltiazem, fendiline, gallopamil, prenylamine, terodiline, verapamil), a dihydropyridine derivative (felodipine, isradipine, nicardipine, nifedipine, nimodipine, nisoldipine, nitrendipine) a piperazinde derivative (e.g., cinnarizine, flunarizine, lidoflazine) or a micellaneous calcium channel blocker such as bencyclane, etafenone, magnesium, mibefradil or perhexyline. In certain embodiments a calcium channel blocker comprises a long-acting dihydropyridine (nifedipine- type) calcium antagonist. [0290] Non-limiting examples of miscellaneous antiarrhymic agents include adenosine (adenocard), digoxin (lanoxin), acecamide, ajmaline, amoproxan, aprindine, bretylium tosylate, bunaftine, butobendine, capobenic acid, cifenline, disopyranide, hydroquinidine, indecamide, ipatropium bromide, lidocaine, lorajmine, lorcamide, meobentine, moricizine, pirmenol, prajmaline, propafenone, pyrinoline, quinidine polygalacturonate, quinidine sulfate and viquidil. [0291] In other embodiments, the ASO of the present application ASO is combined with an antihypertensive agent including, but not limited to, alpha/beta blockers (labetalol (normodyne, trandate)), alpha blockers, anti-angiotensin II agents, sympatholytics, beta blockers, calcium channel blockers, vasodilators and miscellaneous antihypertensives. [0292] Non-limiting examples of an alpha blocker, also known as an α-adrenergic blocker or an α-adrenergic antagonist, include amosulalol, arotinolol, dapiprazole, doxazosin, ergoloid mesylates, fenspiride, indoramin, labetalol, nicergoline, prazosin, terazosin, tolazoline, trimazosin and yohimbine. In certain embodiments, an alpha blocker may comprise a quinazoline derivative. Non-limiting examples of quinazoline derivatives include alfuzosin, bunazosin, doxazosin, prazosin, terazosin and trimazosin. [0293] Non-limiting examples of anti-angiotension II agents include angiotensin converting enzyme inhibitors and angiotension II receptor antagonists. Non-limiting examples of angiotensin converting enzyme inhibitors (ACE inhibitors) include alacepril, enalapril (vasotec), captopril, cilazapril, delapril, enalaprilat, fosinopril, lisinopril, moveltopril, perindopril, quinapril and ramipril. Non-limiting examples of an angiotensin II receptor blocker, also known as an angiotension II receptor antagonist, an ANG receptor blocker or an ANG-II type-1 receptor blocker (ARBS), include angiocandesartan, eprosartan, irbesartan, losartan and valsartan. Non-limiting examples of a sympatholytic include a centrally acting sympatholytic or a peripherally acting sympatholytic. Non-limiting examples of a centrally acting sympatholytic, also known as a central nervous system (CNS) sympatholytic, include clonidine (catapres), guanabenz (wytensin), guanfacine (tenex) and methyldopa (aldomet). Non-limiting examples of a peripherally acting sympatholytic include a ganglion blocking agent, an adrenergic neuron blocking agent, a β-adrenergic blocking agent or an al-adrenergic blocking agent. Non-limiting examples of a ganglion blocking agent include mecamylamine (inversine) and trimethaphan (arfonad). Non-limiting of an adrenergic neuron blocking agent include guanethidine (ismelin) and reserpine (serpasil). Non-limiting examples of a β-adrenergic blocker include acenitolol (sectral), atenolol (tenormin), betaxolol (kerlone), carteolol (cartrol), labetalol (normodyne, trandate), metoprolol (lopressor), nadanol (corgard), penbutolol (levatol), pindolol (visken), propranolol (inderal) and timolol (blocadren). Non-limiting examples of alphal-adrenergic blocker include prazosin (minipress), doxazocin (cardura) and terazosin (hytrin). [0294] In certain embodiments, an antihypertensive agent may comprise a vasodilator (e.g., a cerebral vasodilator, a coronary vasodilator or a peripheral vasodilator). In particular embodiments, a vasodilator comprises a coronary vasodilator including, but not limited to, amotriphene, bendazol, benfurodil hemisuccinate, benziodarone, chloracizine, chromonar, clobenfurol, clonitrate, dilazep, dipyridamole, droprenilamine, efloxate, erythrityl tetranitrane, etafenone, fendiline, floredil, ganglefene, herestrol bis(P-diethylaminoethyl ether), hexobendine, itramin tosylate, khellin, lidoflanine, mannitol hexanitrane, medibazine, nicorglycerin, pentaerythritol tetranitrate, pentrinitrol, perhexyline, pimethylline, trapidil, tricromyl, trimetazidine, trolnitrate phosphate and visnadine. [0295] In certain aspects, a vasodilator may comprise a chronic therapy vasodilator or a hypertensive emergency vasodilator. Non-limiting examples of a chronic therapy vasodilator include hydralazine (apresoline) and minoxidil (loniten). Non-limiting examples of a hypertensive emergency vasodilator include nitroprusside (nipride), diazoxide (hyperstat IV), hydralazine (apresoline), minoxidil (loniten) and verapamil. [0296] Non-limiting examples of miscellaneous antihypertensives include ajmaline, γ-aminobutyric acid, bufeniode, cicletainine, ciclosidomine, a cryptenamine tannate, fenoldopam, flosequinan, ketanserin, mebutamate, mecamylamine, methyldopa, methyl 4- pyridyl ketone thiosemicarbazone, muzolimine, pargyline, pempidine, pinacidil, piperoxan, primaperone, a protoveratrine, raubasine, rescimetol, rilmenidene, saralasin, sodium nitrorusside, ticrynafen, trimethaphan camsylate, tyrosinase and urapidil. In certain aspects, an antihypertensive may comprise an arylethanolamine derivative (amosulalol, bufuralol, dilevalol, labetalol, pronethalol, sotalol and sulfmalol); a benzothiadiazine derivative (althizide, bendroflumethiazide, benzthiazide, benzylhydrochlorothiazide, buthiazide, chlorothiazide, chlorthalidone, cyclopenthiazide, cyclothiazide, diazoxide, epithiazide, ethiazide, fenquizone, hydrochlorothizide, hydroflumethizide, methyclothiazide, meticrane, metolazone, paraflutizide, polythizide, tetrachlormethiazide and trichlonnethiazide); a N- carboxyalkyl(peptide/lactam) derivative (alacepril, captopril, cilazapril, delapril, enalapril, enalaprilat, fosinopril, lisinopril, moveltipril, perindopril, quinapril and ramipril); a dihydropyridine derivative (amlodipine, felodipine, isradipine, nicardipine, nifedipine, nilvadipine, nisoldipine and nitrendipine); a guanidine derivative (bethanidine, debrisoquin, guanabenz, guanacline, guanadrel, guanazodine, guanethidine, guanfacine, guanochlor, guanoxabenz and guanoxan); a hydrazines/phthalazine (budralazine, cadralazine, dihydralazine, endralazine, hydracarbazine, hydralazine, pheniprazine, pildralazine and todralazine); an imidazole derivative (clonidine, lofexidine, phentolamine, tiamenidine and tolonidine); a quanternary ammonium compound (azamethonium bromide, chlorisondamine chloride, hexamethonium, pentacynium bis(methylsulfate), pentamethonium bromide, pentolinium tartrate, phenactropinium chloride and trimethidinium methosulfate); a reserpine derivative (bietaserpine, deserpidine, rescinnamine, reserpine and syrosingopine); or a sulfonamide derivative (ambuside, clopamide, faro semide, indapamide, quinethazone, tripamide and xipamide). [0297] In other embodiments, the ASO of the present application is combined with a vasopressor. Vasopressors generally are used to increase blood pressure during shock, which may occur during a surgical procedure. Non-limiting examples of a vasopressor, also known as an antihypotensive include amezinium methyl sulfate, angiotensin amide, dimetofrine, dopamine, etifelmin, etilefrin, gepefrine, metaraminol, midodrine, norepinephrine, pholedrine and synephrine. [0298] In some embodiments, the ASO of the present application is combined with treatment agents for congestive heart failure including, but not limited to, anti-angiotension II agents, afterload-preload reduction treatment (hydralazine (apresoline) and isosorbide dinitrate (isordil, sorbitrate)), diuretics, and inotropic agents. [0299] Non-limiting examples of a diuretic include a thiazide or benzothiadiazine derivative (e.g., althiazide, bendroflumethazide, beizthiazide, benzylhydrochlorothiazide, buthiazide, chlorothiazide, chlorothiazide, chlorthalidone, cyclopenthiazide, epithiazide, ethiazide, ethiazide, fenquizone, hydrochlorothiazide, hydroflumethiazide, methyclothiazide, meticrane, metolazone, paraflutizide, polythizide, tetrachloromethiazide, trichlormethiazide), an organomercurial (e.g., chlormerodrin, meralluride, mercamphamide, mercaptomerin sodium, mercumallylic acid, mercumatilin dodium, mercurous chloride, mersalyl), a pteridine (e.g., furterene, triamterene), purines (e.g., acefylline, 7-morpholinomethyltheophylline, pamobrom, protheobromine, theobromine), steroids including aldosterone antagonists (e.g., canrenone, oleandrin, spironolactone), a sulfonamide derivative (e.g., acetazolamide, ambuside, azosemide, bumetanide, butazolamide, chloraminophenamide, clofenamide, clopamide, clorexolone, diphenylmethane-4,4'-disulfonamide, disulfamide, ethoxzolamide, furosemide, indapamide, mefruside, methazolamide, piretanide, quinethazone, torasemide, tripamide, xipamide), a uracil (e.g., aminometradine, amisometradine), a potassium sparing antagonist (e.g., amiloride, triamterene) or a miscellaneous diuretic such as aminozine, arbutin, chlorazanil, ethacrynic acid, etozolin, hydracarbazine, isosorbide, mannitol, metochalcone, muzolimine, perhexyline, ticrnafen and urea. [0300] Non-limiting examples of a positive inotropic agent, also known as a cardiotonic, include acefylline, an acetyldigitoxin, 2-amino-4-picoline, aminone, benfurodil hemisuccinate, bucladesine, cerberosine, camphotamide, convallatoxin, cymarin, denopamine, deslanoside, digitalin, digitalis, digitoxin, digoxin, dobutamine, dopamine, dopexamine, enoximone, erythrophleine, fenalcomine, gitalin, gitoxin, glycocyamine, heptaminol, hydrastinine, ibopamine, a lanatoside, metamivam, milrinone, nerifolin, oleandrin, ouabain, oxyfedrine, prenalterol, proscillaridine, resibufogenin, scillaren, scillarenin, strphanthin, sulmazole, theobromine and xamoterol. [0301] In particular aspects, an intropic agent is a cardiac glycoside, a beta-adrenergic agonist or a phosphodiesterase inhibitor. Non-limiting examples of a cardiac glycoside includes digoxin (lanoxin) and digitoxin (crystodigin). Non-limiting examples of a β- adrenergic agonist include albuterol, bambuterol, bitolterol, carbuterol, clenbuterol, clorprenaline, denopamine, dioxethedrine, dobutamine (dobutrex), dopamine (intropin), dopexamine, ephedrine, etafedrine, ethylnorepinephrine, fenoterol, formoterol, hexoprenaline, ibopamine, isoetharine, isoproterenol, mabuterol, metaproterenol, methoxyphenamine, oxyfedrine, pirbuterol, procaterol, protokylol, reproterol, rimiterol, ritodrine, soterenol, terbutaline, tretoquinol, tulobuterol and xamoterol. Non-limiting examples of a phosphodiesterase inhibitor include aminone (inocor). [0302] In certain aspects, the secondary therapeutic agent may comprise a surgery of some type, which includes, for example, preventative, diagnostic or staging, curative and palliative surgery. Surgery, and in particular a curative surgery, may be used in conjunction with other therapies, such as the present invention and one or more other agents. [0303] Such surgical therapeutic agents for hypertrophy, vascular and cardiovascular diseases and disorders are well known to those of skill in the art, and may comprise, but are not limited to, performing surgery on an organism, providing a cardiovascular mechanical prostheses, angioplasty, coronary artery reperfusion, catheter ablation, providing an implantable cardioverter defibrillator to the subject, mechanical circulatory support or a combination thereof. Non-limiting examples of a mechanical circulatory support that may be used in the present invention comprise an intra-aortic balloon counterpulsation, left ventricular assist device or combination thereof. [0304] The present application is further illustrated by the following examples that should not be construed as limiting. The contents of all references, patents, and published patent applications cited throughout this application, as well as the Figures and Tables, are incorporated herein by reference. EXAMPLES Example 1: Materials and Methods Standardized Procedures ASO handling [0305] Each ASO (IDT) was reconstituted in a tube with RNAse free water. [0306] An aliquot of 20 – 50 ul per tube was prepared to prevent freeze-thaw cycles. Cell seeding and transfection condition [0307] Cells were seeded in a 12-well plate and a 6-well plate for total RNA and protein isolation, respectively. [0308] Cells were seeded to achieve 40-50% confluency before transfection. [0309] HEK293T cells were transfected using Lipofectamine 3000 (0.2% concentration), while IHCFs were transfected using LipoRNAiMAX (0.35% concentration). [0310] A transfection of 50 nM of ASOs was performed for 24 hours. Western blotting loading [0311] A gradient curve was created on the left side of the gel by loading control samples at concentrations of 1x, 0.5x and 0.25x. [0312] Following the gradient curve, the experimental samples were loaded. Quantification [0313] The intensity of the gradient curve band was quantified using ImageJ. [0314] A standard curve was plotted, and an equation was derived. [0315] The intensity of the experimental sample bands was quantified using ImageJ. [0316] An arbitrary value was obtained using the equation from the standard curve. [0317] The sample values were normalized with the loading controls (alpha-tubulin, beta-actin or GAPDH). Detailed Procedures Cell culture and transfections [0318] Human HEK293T cells were propagated in Dulbecco's modified Eagle's medium (DMEM; Gibco), and AC16 were propagated in an equal mix of F12:DMEM media (Gibco). Both media were supplemented with 10% fetal bovine serum. When ASO testing, 5x10 5 cells HEK293T or AC16 cells were seeded in 10 cm dishes. Once adhered overnight, the culture medium was changed to OPTI-MEM (Gibco) and transfected with 50 nM ASOs using RNAiMAX (Thermo Fisher Scientific) following manufacture’s guidelines for 6 hr, after which the medium is changed back to the regular culture medium. Cells were harvested 18 hr after transfection. Western blotting [0319] Cells were lysed in RIPA buffer (Thermo Fisher Scientific), and total cell proteins were separated in a 6%–15% denaturing polyacrylamide gel, transferred to polyvinylidene difluoride membranes (PVDF; Amersham Biosciences), and probed using antibodies recognizing GATA4 (Santa Cruz), β-actin (Thermo Fisher Scientific), DDX3X (Sigma), then incubated with either a mouse or rabbit secondary antibody conjugated with horseradish peroxidase (GE Biosciences). Blots were quantified using ImageJ (NIH). Dual-luciferase assay [0320] Untreated HEK293T cells were seeded in 96 well plates at a density of 1x10 4 cells per well and left to adhere overnight. The cells are then transfected each with 50 ng 5’UTR-FLuc reporter plasmid and a control renilla luciferase (RLuc) plasmid using Lipofectamine 3000 (Thermo Fisher Scientific) based on manufacture’s guidelines. After 24 hours, the cells were incubated with Dual-Glo luciferase substrated (Promega) according to the manufacturer’s recommendations. The final readings of the Fluc are then normalized to Rluc to obtain the relative luminescence reading. RNA purification and RT-qPCR [0321] For ASO transfected cells the media was aspirated from adherent cells and then washed twice with chilled PBS. The cells are then lysed by adding 1000 ul of Trizol (Qiagen) directly to the cells, which is then mixed with 200 ul of chloroform in 1.5 ml tubes, and left to on ice for 5 min. The mixture is then spun down at 16,000 g for 10 min. RNA is then precipitated from the aqueous layer by adding two volumes of isopropanol and spinning down at 16,000 g for 10 min. The pellet is then washed twice with 70% ethanol, left to dry, and resuspended in nuclease-free water. For quantitation of mRNA levels, cDNAs were prepared using iScript master mix RT Kit (Biorad) and subsequently qPCR-amplified using SYBR Primer Assay kits (Biorad). Notably, when a primer set was first used, the identity of the resulting PCR product was confirmed by cloning and sequencing. The quantitative nature of each primer was also assessed by performing a standard curve of varying cDNA amount. Once confirmed, melting curves were used in each subsequent PCR to verify that each primer set reproducibly and specifically generates the same PCR product. Polysome Profiling and RNA extraction [0322] Following ASO transfection, cells are incubated with cycloheximide (100 ug/ml; Sigma) for 10 min and then harvested using a native lysis buffer with 100 mM KCl, 5 mM MgCl2, 10 mM HEPES, pH 7.0, 0.5% Nonidet P-40, 1 mM DTT, 100 U ml–1 RNasin RNase inhibitor (Promega), 2 mM vanadyl ribonucleoside complexes solution (Sigma- Aldrich (Fluka BioChemika)), 25 µl ml–1 protease inhibitor cocktail for mammalian tissues (Sigma-Aldrich), cycloheximide (100 ug/ml). The lysate is then spun down at 1500g for 5 min to pellet the nuclei. The supernatant is then loaded onto a 10-50% sucrose gradient and spun in an ultracentrifuge at 150,000g for 2 hours and 20 min. The gradients are then transferred to a fractionator coupled to an ultraviolet absorbance detector that outputs an electronic trace across the gradient. Using a 60% sucrose chase solution, the gradient is then pumped into the fractionator, and divided equally into 12 fractions. RNA was extracted by mixing 500 ul of each fraction is mixed with equal volumes of chloroform: phenol: chloroform: isoamyl alcohol (25:24:1) and 0.1 volumes of 3M sodium acetate (PH 5.2), then spun down at 16,000g for 10 min. The upper aqueous layer was then used to repeat this extraction process. The final upper aqueous later is then mixed with two volumes of 100% ethanol and left to incubate at -20 overnight. The solution is then spun at maximum speed for 30 min to pellet the RNA, which is then washed twice with 70% ethanol, and finally resuspended in nuclease-free water. Immunofluorescence [0323] WGA (5 mg) was dissolved in 5 ml of PBS (pH 7.4). We performed deparaffinization by following steps: (i) Xylene (100%) for 2 × 5 mins; (ii) Ethanol (100%) for 2 × 5 mins; (iii). Ethanol (95%) for 1 × 5 mins; (iv) ddH2O for 2 × 5 min. The slides were kept in a pressure cooker for 10 min along with citrate buffer (10 mM, pH 6.0) for antigen retrieval. We quenched the slides with 0.1 M glycine in phosphate buffer (pH 7.4) for 1 h at RT. Circles were made with a Dako pen, and slides were blocked with goat normal serum for 30 min.10 μg/ml of WGA‐Alexa Fluor 488 (Sigma Aldrich) was applied to the slides for incubation for 1 h at RT. Slides were rinsed in PBS 3 × 5 min. A coverslip was placed on the slides with VECTASHIELD HardSet antifade mounting medium with DAPI (Vectorlabs) for imaging. For AC16 and ESC derived CM cultures, the cells were fixed using a 4% paraformaldehyde in PBS for 10 min, washed with PBS, and permeabilized using 0.2% Triton X‐100 for 10 min. Cells were blocked in 2% BSA/PBS for 1 h and stained with the appropriate primary antibody for 1 hour min at RT, then incubated with secondary fluorescently labelled antibodies. The stained cells were gently washed with PBS for 3 × 5 min, and the slides were mounted using a mounting medium with DAPI. When measuring cell size surface area in heart sections or AC16 slides, five different fields were selected, and the cell size of at least 200 CM cells was measured using Image J. For ESC- derived-CM, it was found it hard to measure cell surface area of these cells in isolation as with AC16 cells. Therefore, we used Image J to measure the whole surface whole colony surface area for at least five colonies per sample, which is then divided by the number of nuclei. Statistics [0324] All quantitative data were presented as mean ± SD and analyzed using Prism 8.3.0 software (GraphPad). For a comparison between two groups, an unpaired two‐tailed Student t-test for normally distributed data were performed. For mouse echocardiography studies, ANOVA followed by Holm-Sidak post hoc test was used to determine the statistical significance among groups. Two‐sided P values < 0.05 were considered to indicate statistical significance. Specific statistical methods were described in the figure legends. [0325] Sequences of ASOs used in this study (5'-3'; “m” indicates a 2'-O-methyl modification, “e” indicates a 2'-O-methoxyethyl modification, “+” indicates LNA, “s” indicates phosphorothioate, and “o” indicates a phosphodiester internucleoside linkage). GATA4 human ASO control: used in human and mouse as a control; underline: mismatch compared to GATA4 ASO1. [0326] All the ASOs were synthesized in IDT, inc.100 nmoles, purified using a desalting column. Analytical ESI-MS confirmed the purity and quality of the ASOs. All the ASOs were synthesized in IDT, inc.100 nmoles, purified using a desalting column. Analytical ESI-MS confirmed the purity and quality of the ASOs. [0327] Fig .10 lists the following: the human GATA4 mRNA sequence (SEQ ID NO:22), mouse GATA4 mRNA sequence (SEQ ID NO:23), human MEF2C mRNA sequence (SEQ ID NO:24), human NKX2-5 mRNA sequence (SEQ ID NO:25), and human eIF4G2 mRNA sequence (SEQ ID NO:26), GATA4 human type I uotASO target sequence (SEQ ID NO:27), GATA4 human type II motASO target sequence (SEQ ID NO:28), MEF2C human type II motASO target sequence (SEQ ID NO:29), NKX2-5 human type II motASO target sequence (SEQ ID NO:30), eIF4G2 human type II uotASO target sequence (SEQ ID NO:31), human, gorilla and monkey GATA4 uORF DNA sequence (SEQ ID NO:32), cat and dolphin GATA4 uORF DNA sequence (SEQ ID NO:33), golden hamster GATA4 uORF DNA sequence (SEQ ID NO:34), rat GATA4 uORF DNA sequence (SEQ ID NO:35), mouse GATA4 uORF DNA sequence (SEQ ID NO:36), WT human GATA4 stem loop region (SEQ ID NO:37), ΔuORF human GATA4 stem loop region (SEQ ID NO:38), Mut human GATA4 stem loop region (SEQ ID NO:39), Rescue Mut human GATA4 stem loop region (SEQ ID NO: 40), EIF4G2-ASO-1-gapmer (SEQ ID NO: 41), Unmodified EIF4G2-ASO-1 (SEQ ID NO: 42), Human MYBPC3 mRNA (SEQ ID NO: 43), Human CRYAB mRNA (SEQ ID NO: 44), MYBPC3 ASO (SEQ ID NO: 44), and CRYAB ASO (SEQ ID NO: 46). Example 2: Downstream dsRNA structure adjacent to uORF inhibits translation of mORF [0328] Double-stranded RNA (dsRNA) structures embedded in 5’UTRs have been reported to inhibit or activate translation dependent on its location and structure features. In addition, upstream open reading frames (uORFs) are known to inhibit the main open reading frame (mORF) translation. To explore the potential crosstalk between such dsRNA structures and uORFs, artificial luciferase reporters containing dsRNA and uORF elements for dual- luciferase reporter assays were constructed (FIG.2, panel A). [0329] Specifically, a series of 5’UTR-firefly luciferase (FLuc) reporter fusions were created from a 5’UTR containing a CA repeat backbone with a stable hairpin Kan-HP140-nt away from the 5’-end and 20-nt away from the FLuc ORF start codon. The 5'UTR was synthesized as oligonucleotides (for both + and - strands) from IDT and then cloned into a FLuc construct that corresponds to mORF. The 5'UTR backbone contained a CA repeat (i.e., [CA]*n) which is known to be a linear sequence. In this backbone, the hairpin was added 40- nt away from the 5' end and 20-nt away from the firefly mORF coding sequence. The hairpin was obtained from the Disney paper because it contained a G at the beginning of it so if an AU is placed before it, it creates a uORF. The AUG was then shifted backward by 3 nucleotides for every reporter up to 27. This backbone was then mutagenized by inserting start codons (i.e., ATG) at various positions spaced by 2 nt up to 23 nt relative to the base of the stem (FIG.2, panel B) Dual-Luc assays showed that start codons at positions -2 and -5 confer the most robust suppression of the luciferase activity; weaker inhibition was conferred at position -8 (FIG.2, panel C). Start codons at positions -8 to -23 conferred no detectable suppression. [0330] To elucidate the role of hairpin stability on uORF activity, mismatches were introduced into the hairpin of the parent construct (not containing AUG) as well as the one containing a start codon at position -2 (AUG -2) (FIG.2, panel D, left). Mutations in the parent sequence confer no suppression over the luciferase activity, whereas mutations in the AUG -2 variant showed rescuing in the luciferase activity, suggesting that the RNA structure stability is needed for the AUG codon to confer suppression. Compared to the parent AUG -2 construct, the mutagenized AUG -2 variants exhibited enhanced luciferase activity and protein levels (FIG.2, panel D, right). Enhanced luciferase activity was also observed from a parent construct in which the AUG was deleted. Taken together, these results demonstrate a functional connection between upstream ATGs or uORFs, RNA structure stability and translation initiation of mORFs. In particular, a dsRNA stem-loop RNA structure located at a proximal location downstream of uORF (2-11 nt away) was found to enhance uORF activity and reduce mORF translation. These results lend support to the discovery that dsRNA stem- loop structures immediately downstream of uORFs can enhance uORF activity and suppress translation of a mORF. [0331] To explore the mechanism underlying the dsRNA-mediated shift of uORF to mORF translation, in vitro transcription of a series of mRNAs with 5'UTRs based on the constructs used in FIG.2, Panel B, was done and then they were incubated in the rabbit reticulocyte lysate (RRL) (FIA). The lysate was then fractionated on a 10-35% sucrose gradient by ultracentrifugation. The hairpin-bearing 5'UTR of the non-AUG-containing reporter with RRL resulted in co-sedimentation of the 5'UTR with the 40S ribosomal subunit, which was not observed in a control 5'UTR lacking the hairpin and a start codon (FIG.3, Panel B, in red), suggesting a hairpin-specific co-sedimentation effect (FIG.3, Panel B, in cyan). Whereas, coupling a start codon with an adjacent downstream hairpin resulted in a shift from the 40S peak in the profile towards an assembled 80S monosome (FIG.3, Panel B, in green) to a greater extent than a start codon alone (FIG.3, Panel B, in yellow), suggesting enhanced translation initiation by a hairpin structure downstream of a start codon. Taken together, these results indicate that the presence of a hairpin downstream of a uORF initiation codon enhances the suppressive capability of the uORF against mORF translation, and this synergistic effect between the start codon and the hairpin dsRNA is abolished when the hairpin stem is destabilized. Example 3: Presence of uORFs in human cardiac transcriptional factor mRNAs [0332] To further investigate a role for dsRNA stem-loop RNA structures and uORFs in suppressing translation of mORFs, a search was conducted to identify naturally existing mRNA transcripts containing one or more uORFs within or surrounding dsRNA structural elements. This was carried out by data mining of unbiased high throughput ribosome profiling (Ribo-seq) databases. Overlapping of Ribo-seq hits uncovered a conserved cohort of mRNAs containing translating uORFs in mice and humans (FIG.4, panel A, left, middle). Gene ontology analysis of overlapping genes revealed transcription factors as the top enriched gene set containing translatable uORF, including GATA4, GATA6, TBX5, TBX20, MYOCD, and NKX2-5 (FIG.4, panel A, right). [0333] Among these 6 transcription factors, GATA4 was of particular interest since GATA4 mRNA contains a single uORF exhibiting ribosome footprints in the human heart by Ribo-seq analysis (FIG.4, panel A, right) and since the GATA4 uORF is conserved across various mammals and includes an 11-nt sequence downstream of the uORF start codon that is highly conserved through evolution. However, the fact that the uORF protein sequences are not conserved suggests that the GATA4 uORF is more likely to be a regulatory element rather than a bioactive peptide. [0334] GATA4 is a key transcription factor required for cardiomyocyte growth and hypertrophy. RNA structure prediction by the TurboFold tool suggested the presence of a 10 base-pair (bp) stem directly downstream of the uORF start codon shown in the illustration of the predicted structure of 5’UTR (FIG.4, panel C). A Selective 2′ Hydroxyl Acylation analyzed by Primer Extension (SHAPE) assay was used to confirm the existence of the double stranded secondary stem structure in the 5'UTR of GATA4 mRNA. In brief, nucleotides located in double-stranded stem structures tend to be less modified by the electrophile, N-methylisatoic anhydride (NAI), while single-stranded regions are exposed for more intense modification. Confirmation of the double-stranded RNA structure was obtained by showing that the predicted 10-bp stem loop downstream of the AUG start codon exhibited the lowest SHAPE activity (data not shown). This result was further evidenced by experiments showing stalling of the 40S ribosome subunit at the hairpin dsRNA region using a toe-printing assay (data not shown). Example 4: GATA4-targeting ASOs regulate GATA4 mORF translation efficiency in cells [0335] The GATA45'UTR variant studies provided an impetus for examining the potential therapeutic effects of using 5’UTR-directed agonists or antagonists to modify GATA4 expression in a therapeutic context. Such studies are predicated on perturbing the activities of the GATA 4 uORF and mORF relative to one another. In this regard, two hypotheses were considered: 1) Disruption of dsRNA structure leads to inactivation of uORF and higher Luc activity; and 2) Sequestration of the uORF results in an increase in its translation, resulting in less Luc activity. The first hypothesis was tested by designing a uORF-suppressing 16-mer ASO (human ASO1, SEQ ID NO:8) mimicking the disruption of the upstream strand by preventing it from the sequestering the uORF-containing strand (FIG. 5, panel A, left). The second hypothesis was tested by designing an uORF-enhancing ASO (human ASO2, SEQ ID NO:3) that can tightly sequester the uORF due to complementary binding, thereby forming a stable 16 bp double-stranded stem (FIG.5, panel B, left). [0336] In dual-Luc assays, ASO1 increased Luc activity, suggesting inhibition of uORF translation, while ASO2 decreased Luc activity, suggesting activation of uORF translation (FIG.5, panel A, right). These effects are uORF dependent, as indicated by the fact that the ΔuORF reporter activity was unchanged with both ASOs (FIG.5, panel B, right). [0337] Targeting the endogenous GATA4 mRNA in AC16 human CMs with these ASOs led to observable protein level changes (FIG.5, panel C). The uORF-suppressing ASO1 increased GATA4 protein levels, while the uORF-enhancing ASO2 reduced it. To further confirm the uORF-mediated translational regulation of mORF, polysome profiling was carried out. The results of this analysis showed that the global polysome profiles stayed unchanged (FIG.5, panel D). Subsequent RT-qPCR analyses demonstrated that WT 5'UTR- bearing FLuc mRNA shifted to the more heavily translated fractions upon ASO1 treatment while less translatable fractions were obtained upon ASO2 treatment (FIG.5, panel E). Inasmuch as no significant changes in mRNA levels were observed (data not shown), it was concluded ASO1 and ASO2 specifically influenced the translation efficiency of the target mRNAs. Thus, when transfected into AC16 cells, ASO1 caused cardiomyocyte (CM) hypertrophy, while ASO2 caused CM atrophy (FIG.5, panel F). Example 5: Optimization and exploration of the utility of Type ASO-mediated biomolecular helix formation in broad applications [0338] As shown in FIG.6, Panel A, a type II uotASO targeting the uORF of the eIF4G2 mRNA result in reduced translation of eIF4G2 mORF and hence reduced amount of eIF4G2 protein as detected by Western blot. Panel B of FIG.6 shows that type II motASOs targeting the mORF of GATA4 mRNA induced enhanced production of GATA4 protein. Specifically, the 2'-O-methyl modified type II motASO produced significant enhancement of GATA4 protein levels to 21.2 ± 2.0% of the control ASO group (FIG.6, Panel A). The ASOs did not alter mRNA expression (FIG.6, Panel B). While the combination of 2'-O- methyl plus 4 LNA nucleotides at the 3'-end of the ASO resulted in an even stronger mORF- enhancing effect without affecting mRNA expression levels (FIG.6, Panel C). Similar mORF-enhancing effect was also observed with type II motASOs targeting the mORFs in the MEF2C mRNA and NKX2-5 mRNA. [0339] Taken together, the ASOs of the present application can decrease harmful proteins or increase beneficial ones. Additionally, the ASOs can increase protein levels in a manner that is simpler than viral delivery methods (Data not shown). Long-standing needs for overexpressing therapeutic proteins exist to treat diseases caused by genetic haploinsufficiency or pathogenic depletion. Alternatively, cell identity switch is a promising approach to improve organ function and reverse disease progressions, such as cardiac fibroblast-to-CM trans-differentiation driven by overexpressing a cocktail of TFs, including GATA4, MEF2C, TBX5, and NKX2-5. This application has provided “proof-of-concept” evidence to support the idea of increasing protein levels of GATA4, MEF2C, and NKX2-5 by ~1.5-3 fold using the type II motASOs. Another scenario where type II motASOs can be of use is if the mRNA desired for overexpression is too large (e.g., Titin) for viral delivery approaches. [0340] Cell identity switch is a promising approach to improve organ function and reverse disease progressions, such as cardiac fibroblast (CF)-to-cardiomyocyte (CM) trans- differentiation driven by overexpressing a cocktail of TFs, including GATA4, MEF2C, TBX5, and NKX2-5. Therefore, enhanced protein expression of GATA4, MEF2C, or NKX2- 5 by type II motASOs will likely compromise cardiac fibrosis as a result of CF-to-CM transition. On the other hand, eIF4G2 promotes pro-fibrotic extracellular matrix protein translation and contributes significantly to cardiac fibrosis (unpublished results from our lab). Therefore, type II uotASO that promotes uORF activity and inhibits eIF4G2 mORF translation will reduce cardiac fibrosis. Example 6: CRYAB and MYBPC3 Type II motASOs increase protein expression but not mRNA expression [0341] A platform has been developed whereby users can design Anti-Sense Oligonucleotides (ASOs) that bind specific regions within the main open reading frame (mORF) of mRNA and selectively increase mRNA translation and protein synthesis (Type II motASO) (FIG.7A). This study selected two mRNA targets (MYBPC3 and CRYAB) of interest to focus on. MYBPC3 and CRYAB are myofilaments and heat shock proteins, respectively, required for normal cardiomyocyte contractile function. The proteins encoded by these two target mRNAs are known to protect the heart from cardiac fibrosis when overexpressed in cardiomyocytes (FIG.7B). [0342] MYBPC3 (myosin binding protein C3) encodes the cardiac isoform of myosin-binding protein C. Myosin-binding protein C is a myosin-associated protein found in the cross-bridge-bearing zone (C region) of A bands in striated muscle. MYBPC3 is expressed exclusively in the heart muscle and is a key regulator of cardiac contraction. Heterozygous mutations in this gene are a frequent cause of familial hypertrophic cardiomyopathy caused by haploinsufficiency. [0343] CRYAB (crystallin alpha B): Mammalian lens crystallins are divided into alpha, beta, and gamma families. Alpha crystallins are composed of two gene products: alpha-A and alpha-B, for acidic and basic, respectively. Alpha crystallins can be induced by heat shock and are members of the small heat shock protein (HSP20) family. They act as molecular chaperones although they do not renature proteins and release them in the fashion of a true chaperone; instead, they hold them in large soluble aggregates. These heterogeneous aggregates consist of 30-40 subunits; the alpha-A and alpha-B subunits have a 3:1 ratio, respectively. Two additional functions of alpha crystallins are an autokinase activity and participation in the intracellular architecture. The encoded protein has been identified as a moonlighting protein based on its ability to perform mechanistically distinct functions. Alpha-A and alpha-B gene products are differentially expressed; alpha-A is preferentially restricted to the lens and alpha-B is expressed widely in many tissues and organs. Elevated expression of alpha-B crystallin occurs in many neurological diseases; a missense mutation co-segregated in a family with a desmin-related myopathy. Alternative splicing results in multiple transcript variants. [0344] As described herein, the study designed, generated, and evaluated ASOs that have the potential to selectively increase the protein synthesis of these two targets (FIG.7B) ((16-nt MYBPC3 ASO for mRNA translational activation using Type II motASO targeting mORF: CmoUmoUmoCmoCmoCmoCmoGmoGmoCmoUmoCmoAmoGmoGmoCm (SEQ ID NO: 45); 16-nt CRYAB ASO for mRNA translational activation using Type II motASO targeting mORF GmoUmoGmoGmoAmoUmoGmoGmoCmoGmoAmoUmoGmoUmoCmoCm (SEQ ID NO: 46)). [0345] Bioinformatic analysis of mRNA sequence and structure was followed by designing multiple candidate ASOs targeting double-stranded RNA (dsRNA) around upstream open reading frame (uORF) and main ORF (mORF) for in vitro testing. ASOs were designed based on predicted mRNA 5' UTR structure or 5' UTR sequence features and then manufactured. The efficiency of candidate ASOs in manipulating protein expression of the two targets in relevant cell lines in vitro was determined. The target gene mRNA and protein expression was the regulatory readout. The translational activation effects of candidate ASOs was tested using Western blotting (measure protein steady-state level) and RT-qPCR (measure mRNA steady-state level), in AC16 human cardiomyocyte (CM; Sigma #SCC109) cell for CRYAB, MYBPC3 (cardiomycyte protection). [0346] The study identified two 16-nt ASOs (with 2’-O-methyl modifications) targeting MYBPC3 and CRYAB mRNAs for translational activation. The data suggested that the two Type II motASOs can increase protein expression of MYBPC3 and CRYAB in the AC16 human cardiomyocyte cell line in a dose-dependent manner without affecting mRNA expression (FIG.8, panels A-C). Example 7: 5’-UTR-targeting Gapmer ASO reduces elFG4G2 protein expression in immortalized human cardiac fibroblasts [0347] eIF4G2, an essential translation factor for extracellular matrix protein synthesis, has been discovered as a potential anti-fibrotic target gene in cardiac fibroblasts. A 20-nt long ASO is designed to target an evolutionarily conserved region (in humans and mice) that partially overlaps with the upstream open reading frame (uORF) with the combined feature of the Gapmer formula (10 DNA nucleic acids in the center of the ASO plus 5 RNA nucleic acids with phosphorothioate linkage) (FIG.8, panel A and panel B, 5’- UTR-targeting Gapmer ASO, GesCesCesAesCesCdsTdsCdsCdsAdsTdsAdsGdsAdsGdsCesUesCesCesGe (SEQ ID NO:41), wherein e:MOE modification; s:phosphorothioate; d:DNA; unmodified seq: GCCACCTCCATAGAGCUCCG (SEQ ID NO: 42) = target 5’UTR of both eIF4G2 human & mouse). [0348] Bioinformatic analysis of mRNA sequence and structure was followed by designing multiple candidate ASOs targeting double-stranded RNA (dsRNA) around upstream open reading frame (uORF) and main ORF (mORF) for in vitro testing. ASOs were designed based on predicted mRNA 5' UTR structure or 5' UTR sequence features and then manufactured. The efficiency of candidate ASOs in manipulating protein expression of the two targets in relevant cell lines in vitro was determined. The target gene mRNA and protein expression was the regulatory readout. The translational activation effects of candidate ASOs was tested using Western blotting (measure protein steady-state level) and RT-qPCR (measure mRNA steady-state level), in immortalized human cardiac fibroblast (IHCF; abm #T0446): eIF4G2 (anti-fibrosis effect). [0349] One of ordinary skill in the art will recognize that the wings and the gaps discussed above may be selected and then combined in a variety of combinations to generate gapped oligomeric compounds, including, but not limited to, gapped antisense oligomeric compounds, and gapped antisense oligonucleotides. The features (length, modifications, linkages) of the 5′ wing and the 3′ wing may be selected independently of one another. The features of the gap include at least one difference in modification compared to the features of the 5′ wing and at least one difference compared to the features of the 3′ wing (i.e., there must be at least one difference in modification between neighboring regions to distinguish those neighboring regions from one another). The features of the gap may otherwise be selected independently. [0350] This ASO can significantly reduce EIF4G2 mRNA and protein expression via RNase H-mediated mRNA degradation (FIG.9, panels A-C). [0351] Taken together, these results of Examples 6 and 7 herein, show that Type II motASOs and 5’ UTR-targeting Gapmer ASOs can efficiently activate mRNA translation and silence protein expression, respectively. Using these two kinds of ASOs, users are able to either enhance the translation of anti-fibrosis mRNAs or inhibit the expression of pro-fibrotic proteins, thereby achieving potential anti-fibrotic effects in vitro or in vivo. LIST OF SEQUENCES
“m” indicates a 2'-O-methyl modification, “e” indicates a 2'-O-methoxyethyl modification, “+” indicates LNA, “s” indicates phosphorothioate, and “o” indicates a phosphodiester internucleoside linkage, “d” indicates DNA [0352] Herein incorporated is the sequence listing file 1134-119 PCT.xml, created on August 18, 2023, and size of 10,400 bytes. [0353] While various embodiments have been described above, it should be understood that such disclosures have been presented by way of example only and are not limiting. Thus, the breadth and scope of the subject compositions and methods should not be limited by any of the above-described exemplary embodiments but should be defined only in accordance with the following claims and their equivalents. [0354] The above description is for the purpose of teaching the person of ordinary skill in the art how to practice the present invention, and it is not intended to detail all those obvious modifications and variations of it which will become apparent to the skilled worker upon reading the description. It is intended, however, that all such obvious modifications and variations be included within the scope of the present invention, which is defined by the following claims. The claims are intended to cover the components and steps in any sequence which is effective to meet the objectives there intended, unless the context specifically indicates the contrary.
Next Patent: MIXING AND MATCHING VOLUMETRIC CONTENTS FOR NEW AUGMENTED REALITY EXPERIENCES